

INDEX

Volume Seventeen—January through December 1983

DRUG INTELLIGENCE AND CLINICAL PHARMACY

JANUARY	Pages 1-80	JULY/AUGUST	Pages 489-608
FEBRUARY	Pages 81-160	SEPTEMBER	Pages 609-696
MARCH	Pages 161-240	OCTOBER	Pages 697-776
APRIL	Pages 241-320	NOVEMBER	Pages 777-864
MAY	Pages 321-400	DECEMBER	Pages 865-960
JUNE	Pages 401-488		

A

ACCP see American Association of Colleges of Pharmacy
Abbreviated new drug applications, pre-1962 drugs (WNC) 397

Abramowitz, Paul W. (coauthor) see Ludwig, Dennis J., 463, 849

Abrams, W.B. (coauthor) see May, C.A., 443

Abstracts see American College of Clinical Pharmacy; see Foreign Abstracts, 71, 146, 231, 307, 390, 479, 597, 680, 769, 856, 934

ACCP see American College of Clinical Pharmacy

Acetaminophen, adverse reactions, cirrhosis (CTF) 851

liver disease (CTF) 475; interactions, coumarin (DIR) 108

Acetazolamide, ophthalmology (CTF) 303

Aceto-hydroxamic acid, orphan drug made available (WNC) 774

Acetylcholine, adverse reactions, anaphylactic-type reaction (CTF) 224

Achari, Ramanuj (coauthor) see Mayersohn, Michael, 131

Ackerman, Bruce (author) Comparison of

Radioimmunoassay and Fluorescent Polarization

Immunossay for Measurement of Serum Vancomycin

Concentrations (ab), 444; (author) Moxalactam

Therapy for Nosocomial Gram-negative Pneumonias

(ab) 433; (author) Observed Changes in Gentamicin

Pharmacokinetic Parameters and Dosage

Recommendations with Radioimmunoassay and

Fluorescent Polarization Immunossay Methods (ab),

444; (author) Pharmacokinetics of Cefazidime (ab)

444

Acne, cystic, isotretinoin use (NDE) 329

Acquired immune deficiency syndrome, new FDA

guidelines, plasma centers and blood banks (WNC)

484; nitrates (WNC) 154; (A) 801; opportunistic

infections (A) 798; report of interagency

recommendations (WNC) 398; role of T-cell,

discussion (A) 798, human leukemia virus (WNC) 606,

(A) 801; update (WNC) 775

Activated coagulation time, adjusting heparin infusion

rates (A) 632

Acyclovir, clinical trials (NDE) 626; drug administration

(NDE) 625; infectious disease (CTF) 63, 383, 673, 760,

850; mechanism of action (NDE) 624; ophthalmology

(CTF) 223; pharmacokinetics (NDE) 624; resistance

(NDE) 624; spectrum of activity (NDE) 624; topical,

use in herpes (DIAS) 809; toxicity (NDE) 625

Adams, John, VIP (NDE) 863

Adams, Stephen C. (coauthor) see Dozier, Nicky, 798

Adelman, Martin H. (coauthor) see Schentag, Jerome J.,

528

ADH see Antidiuretic hormone

Adverse drug reactions see Drugs, Adverse Reactions

Advertising, drugs, prescription, to consumer (WNC) 79,

(WNC) 862, (WNC) 940, television use (WNC) 606

Ahsanuddin, Khaja M. (coauthor) see DeVane, C.,

Lindsay, 562

Akers, I. (coauthor) see Reed, Michael D., 446

Alam, Abu S. (coauthor) see Baske, David M., 765

Albuterol, cardiovascular disease (CTF) 302; as

salbutamol (A) 178

Alcohol, interactions, moxalactam (CTF) 141

Alexander, Bruce (coauthor) see Perry, Paul J., 449

Alexander, Michael R. (author) Drug Deficiency States

(E) 295

Alfentanil, pharmacokinetics in gynecological surgical

patients (ab) 437

Aljama, Pedro (coauthor) see Jimenez-Alonso, Juan, 752

Alpha-fetoprotein, blood test kits approvable by FDA

(WNC) 774

Alprazolam, psychiatry (CTF) 761

Amann, Anton H. (coauthor) see Yacobi, Avraham, 255

Amantadine, treatment of neuroleptic malignant

syndrome (LA) 640

Ambruse, Peter J. (coauthor) see Tindula, Robert J., 906

Amebiasis, drug regimen in pregnancy (DIAS) 187

American Association of Colleges of Pharmacy,

retroactive degrees (WNC) 79; 1983 meeting,

comments by president George Zografis (WNC) 863

American College of Apothecaries, Lascoff Award

(WNC) 319

American College of Clinical Pharmacy, abstracts of

meeting papers, 433; committee on clinical pharmacy

as a specialty, background, 594, comment by

president, 675; definitions, clinical pharmacist, 593,

clinical pharmacy, 593; fellowship award, infectious

disease, 764; index to abstracts, 454; meeting, 1982

annual, therapeutic frontiers lecture (A) 357; meeting,

1983 annual, abstracts, 433, call for, 74, index, 454,

fellowship award, 764, highlights, 762, NSAID

symposium, 763, pharmacy industry forum, 763,

president's award, 764, president's speech, 675,

schedule for, 225, therapeutic frontiers lecture award,

764, therapeutic symposium, 762; meeting, 1984

annual, call for papers, 759, 854, 913; membership,

criteria, 593, fellow category, background, 594,

comment by president, 675; news, ACCP: Quo

Vadis?, 593, annual meeting highlights, 762, clinical

pharmacists as principal investigators, letter to FDA

with reply, 675, president's speech, 675, schedule of

events for 1983 annual meeting, 225; research, clinical,

principal investigators, FDA policy, 676; research

institute, background, 594, chairman meets with HHS

secretary (WNC) 319; comment by president, 675,

1982 research award, 763, 1983 award, 764; seminars,

regional educational, background, 594, comment by

president, 675, with Academy of Pharmaceutical

Sciences, 676, with University of Texas, 215;

therapeutic frontiers lecture, 1982 paper (A) 357, 1983

award, 764

American Pharmaceutical Association, Board of Trustees

elected (WNC) 319

American Public Health Association, 1983 meeting,

pharmacy session, topics presented (WNC) 863

American Society of Consultant Pharmacists, annual

meeting (WNC) 319

American Society of Hospital Pharmacists, Milton W.

Skolaut terminates office as Treasurer (WNC) 319

Amikacin, effect on urinary enzyme excretion (L) 752;

hemodialysis in critically ill patients (ab) 437;

infectious disease (CTF) 63, 303; pharmacokinetics on

a microcomputer (A) 35

Amiloride, adverse reactions, decreased serum potassium

(CTF) 384; hyponatremia (A) 176; interactions, lithium

(DIAS) 809

Aminocaproic acid, adverse reactions, acute necrotic

myopathy (CTF) 64

Aminoglutethimide, oncology (CTF) 674

Aminoglycosides, comment on monitoring serum levels

(L) 49; falsely elevated serum levels in jaundiced

patients (CR) 544; feasibility study of outpatient

intravenous administration (ab) 435; hypomagnesemia

(A) 181; interactions, magnesium sulfate (CTF) 674;

netilmicin (NDE) 83; pharmacokinetics on a

microcomputer (A) 33

Aminophylline, pharmacokinetics, dosage (CR) 202,

probenecid effect (RPR) 465; see also Theophylline

Amiodarone, adverse reactions, pulmonary toxicity (CTF)

304; clinical efficacy (A) 102; effect on digoxin,

suppression of red blood cell uptake in vitro (ab) 445;

interactions, digoxin (A) 103, quinidine (DIR) 105,

warfarin (A) 103; pharmacokinetics (A) 101;

pharmacology (A) 100; side effects (A) 103

Amiripryline, adverse reactions, acute dystonic reaction

(CTF) 141, malignant hypertension (CTF) 224;

pediatrics (CTF) 63

Amiripryline/tranylcypromine, psychiatry (CTF) 851

Amoxapine, adverse reactions, agranulocytosis (CTF) 925,

akathisia and cogwheel rigidity (CTF) 384,

neurotoxicity (L) 131, tardive dyskinesia (CTF) 592;

toxicology (CTF) 304

Amphotericin B, associated with water loss (A) 177;

fungal infections, associated with acquired immune

deficiency syndrome (A) 803; hypokalemia (A) 177;

hypomagnesemia (A) 181; pediatrics (CTF) 674;

transient asystole, associated with infusion (CR) 547

An Opinion, Covington, Timothy R., Toward a Rational

Approach to the Issue of Prescribing Authority for

Pharmacists, 660; Doering, Paul L., Clinical

Pharmacy: Two Steps Forward, One Step Back, 564;

Fisher, Diane J., The Gap Between Basic Sciences and

Clinical Pharmacy Practice: Is It Epistemological?, 210

Analgesics, efficacy of opioids (DSP) 411

Andersen, Judith M. (coauthor) see Sher, Alam, 551

Anderson, Donald A. (author) Commercial IV Fluid

Overfill Effects on Continuous-Infusion Drug

Administration and Assessment (L) 847

Anemia, hemolytic, induced by cefoxitin (CR) 816

Anesthesiology (CTF), bupivacaine, 760; cimetidine, 924;

diabetes mellitus, 139; epinephrine, 222; etomidate, 850;

flunitrazepam, 62; haloperidol, 302; lidocaine, 673;

midazolam, 139; morphine, 222, 591; nitrous oxide,

383; pericardial disease, 591

Angaran, David (coauthor) see Fletcher, C.V., 447

Anaesthetics, effect on bioavailability of a sustained-release

theophylline preparation (RPR) 555; interactions,

cimetidine (A) 114, (ab) 439

Antiarhythmic, cardiovascular disease (CTF) 591

Antibiotics, changes in certification (WNC) 78; computer-

based trend analysis of parenteral use patterns (ab)

448; interactions, cimetidine (A) 113

Anticancer drugs, reactions and interactions in handling

(A) 532

Anticholinergics, use, nursing home, study and review (A)

470

Anticonvulsants, dosage, calculator procedure for

phenytoin (A) 890; interactions, quinidine (CR) 819,

valproic acid (CTF) 384

Antidepressants, imipramine bulimia nervosa (LA) 815;

psychiatry (CTF) 674; treatment bulimia nervosa (LA)

815; tricyclics, adverse reactions, skin rashes (CTF) 64,

dental caries (DIAS) 810, precipitation of seizure

activity (CR) 644, thyroid, enhancement of therapeutic

effect (DIAS) 718

Antidiuretic hormone, imbalance, drug management (A)

886

Antihistamines, interactions, cimetidine (A) 114

Antimicrobials, subminimum inhibitory concentrations (L)

560

Antineoplastic agents see also Cancer, chemotherapy;

alkylating, adverse reactions with (CTF) 304; safe

handling of parenterals (WNC) 238

Antithyroid drugs, adverse reactions with, agranulocytosis

(CTF) 384

Aprindine, safety and efficacy of long-term oral therapy (ab) 435

Arbones, Gloria (coauthor) see **Mas, Xavier**, 378

Arbus, Marvin (author) Corrections to Drug Information Article (L) 655

Archambault see also **Editorials**, 80, 155, 240, 320, 400, 486, 608, 690, 776, 864, 942

Archambault, George F., resig position (WNC) 940; (author) Archambault: Accolades to Dale E. Wurster (E) 942; A Potential Step Backward for Pharmacy (E) 864; Dangers in Deregulation (E) 320; How Effective Are the New Dosage Forms? (E) 486; Matters Mostly Associational in Nature (E) 690; The "Switch" is On (E) 155; The Legal Standard of Foreseeability as Applied to Legend-Drug-Product Tampering—Or Unit-Of-Use Packaging Revisited (E) 400; The Orphan Drug Products—Another Solution? (E) 80; USAN and the USP Dictionary of Drug Names—Who Needs It? (E) 608; Wondering and Musing (A) 917; (editor) Washington News and Comments, 77, 152, 237, 317, 397, 484, 606, 687, 774, 862, 940

Armstrong, D. (author) Hemodialysis of Amikacin in Critically Ill Patients (ab) 437

Armstrong, Ed (author) Lysine for Herpes Simplex Virus (DIAS) 186

Armas, Josep Maria (coauthor) see **Mas, Xavier**, 378

Arnetti, Graziano (coauthor) see **Messori, Andrea**, 890

Arthroplasty, total joint, ceforanide vs. cephalothin (RPR) 645

Artificial sweeteners, status (WNC) 606

Asdourian, George K. (coauthor) see **Canada, Andrew T.**, 100

Ashtabugh, Richard, VIP (WNC) 319

Asparaginase, adverse reactions, allergic reaction (CR) 130; hyperthermia (CTF) 674

Aspirin, adverse reactions, coronary artery spasms and angina (CTF) 592; submucosal hemorrhages (CTF) 384; cardiovascular disease (CTF) 62, 924; effect of brand on serum level (CR) 550; interactions, cimetidine (A) 114, ethanol (DIR) 107; lithium (CTF) 592; obstetrics/gynecology (CTF) 140; pulmonary disease (CTF) 674; toxicology (CTF) 304

Assassin bug, case report of bite (L) 753

Association News (WNC), AACP: denounces retroactive degrees, 79, excerpts from address by AACP president, 863; ACA: Raymond A. Gosselin meets J. Leon Lascoff Memorial Award, 319; ACCP: meets with Margaret Heckler of HHS, 319; APHA: election results, 319; APHA: meeting, pharmacy sessions, 863; APT: pharmacy technicians first meeting, 941; ASCP: annual meeting, 319; ASHP: Milton W. Skolaut becomes Treasurer Emeritus, 319; Association of Military Surgeons: news, 238; FDLI: drug promotion under NDA (WNC) 79, seminars held, 688, teaching grants available, 775; PMA, names 1983 pharmacy school faculty participants, 941; RAPS: annual meeting, 238, 319

Asthma, treatment, methylxanthines combined with beta-adrenergic agonists (RPR) 820

Atenolol, efficacy and safety in paroxysmal supraventricular tachycardia (ab) 440

Auranofin, adverse reactions, glomerulonephritis (CTF) 141

Avascular bone necrosis, associated with corticosteroids (DIAS) 343

Ayoub, E. (coauthor) see **Hill, Malcolm R.**, 452

Azaproprone, interactions, phenytoin (DIR) 106

Azimexon, immunoreactive agent in acquired immune deficiency syndrome (A) 801

B

Baaske, David M. (author) Author's Reply: Comment on Nitroglycerin Article (L) 754; (author) book review, 765; (coauthor) see **Yacobi, Abraham**, 255

Bachmann, K. (coauthor) see **Schwartz, J.**, 438

Baciewicz, Anne M. (author) Digoxin Resin in the Treatment of Digoxin Toxicity (CR) 57

Baclofen, adverse reactions, convulsions (CTF) 64

Bahntge, Michael F. (coauthor) see **Creger, Richard J.**, 202

Ball, William D. (coauthor) see **Creger, Richard J.**, 202

Ballentine, Ron (author) book review, 926; (coauthor) see **Dostier, Nicky**, 798

Barium, hypokalemia (A) 178

Barke, Jeffrey I. (coauthor) see **Barna, Peter**, 653

Barkin, Robert L. (coauthor) see **Stein, Z.L.G.**, 376, 561, 753

Barna, Peter (author) Ephedrine-Phenobarbital Formulations (L) 653

Barriere, Steven L. (author) Prevention and Treatment of Traveler's Diarrhea (DIAS) 265; (coauthor) see **Chow, Belle L.**, 809; (coeditor) see **Hart, Linda L.**, 264, 342, 629, 718, 808

Barrios, Luciano (coauthor) see **Jimenez-Alonso, Juan**, 752

Barson, W.J. (coauthor) see **Nahata, Milap C.**, 439

Bartoli, Carlo (coauthor) see **Messori, Andrea**, 890

Batenhorst, Randal L. (coauthor) see **Bottoff, Michael B.**, 279

Bauer, L.A. (author) Diurnal Variability in Valproic Acid Clearance (ab) 434

Baumert, R. (coauthor) see **Bauman, Jerry L.**, 435; (coauthor) see **Hoff, J.V.**, 440

Bauman, Jay H. (coauthor) see **Gaginella, Timothy S.**, 873

Bauman, Jerry L. (author) Safety and Efficacy of Long-Term Oral Aprindine (ab) 435

Beach, C.L. (author) Clinical Assessment of a Two-Compartment Bayesian Forecasting Method for Lidocaine in Hospitalized Patients (ab), 450; (coauthor) see **Farrington, J.A.**, 450

Beck, Diane E. (author) Comments and Corrections on Dosing Guidelines (L), 911

Becker, Robert E. (coauthor) see **Weber, Stanley S.**, 523

Bejarano, Rafael (coauthor) see **Jimenez-Alonso, Juan**, 752

Bellur, S. (coauthor) see **Goff, D.**, 441

Bendayan, R. (author) The Influence of Age and Experimental Temperature on Serum Protein Binding of Propranolol (ab) 435

Benedict, comment on (E) 826; labeling, changed (WNC) 78; litigation, comment on (E) 826, (L) 848; recall, comment on (E) 826; teratogenicity, comment on (E) 826

Benedict, L. Kirk (coauthor) see **Kimberlin, Carole L.**, 297

Benfell, Kathleen (coauthor) see **Vogenberg, F. Randy**, 912

Benoxaprofen, authorized by FDA (WNC) 318, (CTF) 924

Benzie, Jennifer L. (author) Drug Management of Antidiuretic Hormone Imbalance Following Pituitary Surgery (A) 886

Benzoazepines, interactions, cimetidine (A) 111, oral contraceptives (CTF) 592

Berence, Sister Mary, editorial comment on (E) 45

Berg, H. (coauthor) see **Ackerman, Bruce**, 444

Berg, Mary J. (coauthor) see **Leff, Richard D.**, 448

Berman, Alex (author) It's A Bazaar, Then? No, It's A Drugstore! (E) 209

Bessinger, F.B. (coauthor) see **Schaber, D.E.**, 439

Beta-blockers, adverse reactions, acute psychosis (CTF) 761; metabolic effects (CTF) 761, renal function (CTF) 304; interactions, cimetidine (A) 112

Bethanechol, gastroenterology (CTF) 63

Bhatia, Subhash C. (coauthor) see **Sher, Alam**, 551

Bibliographies, critical care (CC) 722; parenteral nutrition (A) 189

Bishop, M.P. (author) Neurotoxicity with Amoxapine Overdose: A More Reasonable Perspective (L) 132

Bivins, Brack A. (coauthor) see **Rapp, Robert P.**, 458

Blackman, Marie S. (coauthor) see **Rodgers, George C.**, 819

Blair, Charles W. (coauthor) see **Guernsey, Brock G.**, 742

Block, A.J. (coauthor) see **Gotz, Vincent P.**, 434

Blood levels, carbamazepine, correlation with cholesterol (A) 812; cholesterol, correlation with carbamazepine (A) 812; digoxin, predictability (RPR) 821

Blood pressure, comparison of effects of two dosage regimens of phenylpropanolamine (RPR) 746

Blumenthal, P. (coauthor) see **Stile, I.L.**, 440

Blumer, J.L. (coauthor) see **Reed, Michael D.**, 446

Boer, H.R. (coauthor) see **Peter, J.**, 434

Boike, Steven C. (author) Zomepirac-Related Acute Renal Failure (CR) 56

Book Reviews, Advances in Pharmacology and Chemotherapy, Vol 19 (S. Garattini, A. Goldin, F. Hawking, and J. Kopin) 926; Aminoglycoside Otolotoxicity (S.A. Lerner, G.J. Matz, and J.E. Hawkins) 145; Analytical Profiles of Drug Substances, Vol. 11 (K. Florey) 595; Calcium Blockers: Mechanisms of Action and Clinical Applications (S.F. Flaim and R. Zelis) 478; Cardiac Arrhythmias: A Decade of Progress (D.C. Harrison) 229; Clinical Toxicology of Drugs: Principles and Practice (V.A. Skoutskis) 306; Clinical Use of Drugs in Patients With Kidney and Liver Disease (R.J. Anderson and R.W. Schrier) 228; Controlled Released Nitroglycerin in Buccal and Oral Form (W.D. Bussman and W. Wagner) 765; Drug Therapeutics, Concepts For Physicians (K.L. Melmon) 228; Drug Treatment of the Elderly Patient (T.G. Judge and F.I. Caird) 595; Drug Use in Pregnancy (J.R. Nienly) 679; Drug-Induced Ocular Side Effects and Drug Interactions, 2nd Ed. (F.T. Fraunfelder and S.M. Meyer) 765; Drugs and Drug Abuse: A Reference Text (T.C. Cox, M.R. Jacobs, A.E. LeBlanc, and J. Marshman) 388; Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk (G.G. Briggs, T.W. Bodendorf, R.K. Freeman, and S.J. Yaffe, 852; Handbook of Clinical Drug Data, 5th Ed. (J.E. Knoben and P.O. Anderson) 595; Hospital Pharmacy (W.E. Hassan) 69; Iatrogenic Diseases, 2nd Ed. Update 1981 (P.F. D'Arcy and J.P. Griffin) 228; Index Nominum 1982, 11th Ed., 145; Manual of Antibiotics and Infectious Diseases, 4th Ed. (J.E. Conte, Jr. and S.L. Barriere, 144; Manual of Laboratory Pharmacokinetics (S.H. Curry and R. Welpton) 853; Manual of Oncology Therapeutics (K. See-Lasley and R.J. Ignoffo) 144; Martindale, The Extra Pharmacopoeia, 28th Ed. (J.E.F. Reynolds) 478; Nursing Pharmacology and Therapeutics (M.C. Gerald and F.V. O'Bannon) 69; Pathophysiology of Shock, Anoxia, and Ischemia (R.A. Crowley and B.E. Trump) 387; Pharmacokinetics, 2nd Ed. (M. Gibaldi and D. Perrier) 679; Pharmacologic Principles of Cancer Treatment (B. Chabner) 387; Pharmacology for the Anesthesiologist (B.K. Basak) 68; Pharmacology, 4th Ed. (R.A. Woodbury, W.B. Wood, F.D. Sticht, and E.E. Elko) 69; Pharmacology of Alcohol (D.B. Goldstein) 927; Pharmacology of Hydroxyethyl Starch: Use in Therapy and Blood Banking (J.M. Mishler IV) 926; Pharmacy Practice: Social and Behavioral Aspects, 2nd Ed. (A.I. Wertheimer and M.C. Smith) 852; Practical Guide to Geriatric Medications (R.J. Burant) 68; Problem-Oriented Primary Care, 2nd Ed. (J.W. Runyan, Jr.) 306; Psychopharmacology for Everyday Practice (T.A. Ban and M.H. Hollender) 926; Quality Assurance in Hospital Pharmacy, Strategies & Techniques (M. Lamm and G.L. Snodgrass) 927; Side Effects of Drugs, Annual 7 (M.N.G. Birkbeck and J. Ellis) 765; Fardive Dyskinesia and Related Involuntary Movement Disorders (J. DeVaugh-Geiss) 852; The Yearbook of Drug Therapy: 1982 (L.E. Hollister and L.C. Lasagna) 229

Books Received, 70, 145, 229, 307, 388, 478, 595, 679, 853, 927

Borchert, W. (coauthor) see **Selfert, Randall**, 451

Bosso, John A. (author) Feasibility Study of Outpatient Intravenous Aminoglycoside Administration (ab) 435; The Role of the Institutional Review Board in Research Involving Human Subjects (A) 828

Bottoff, Michael B. (author) High-Dose Procainamide in Chronic Renal Failure (CR) 279

Bradberry, J. Chris (coauthor) see **Sagvares, Rosalie**, 901

Brandstetter, Robert O. (author) Recurrence of Intravenous-Diazepam-Induced Phlebitis from Oral Diazepam (CR) 125

Brass, C. (coauthor) see **Slaughter, Richard L.**, 440

Breckinridge, Michael F. (coauthor) see **Julia, Angiolina M.**, 580

Britton, Lynn (author) Corrections to Drug Information Letter (L), 913

Broccoli, interactions, warfarin (CTF) 761

Brockway, B.A. (coauthor) see **Talbert, Robert L.**, 442

Bromocriptine, acute overdose (CR) 374; adverse reactions, acute psychosis (CTF) 304; obstetrics/gynecology (CTF) 474

Brompheniramine, pediatrics (CTF) 475

Brown, Ronald R. (coauthor) see **Ward, Thomas T.**, 552

Browne, Jerry (author) Author's Reply: Neurotoxicity With Amoxapine Overdose: A More Reasonable Perspective (L) 131; (coauthor) see **Perry, Paul J.**, 449

Brushwood, David B. (author) Two Legal Issues: Expert Witnesses and Benedict Case (L) 848

Bryant, P.J. (author) A Unique Clinical Trial Design to Determine the Single Dose-Dose Response Profile for Investigational Drugs (ab), 445

Bryant, Stephen G. (coauthor) see **Guernsey, Brock G.**, 742, 754

Buchanan, E. Clyde (coauthor) see **Kaka, Jazar S.**, 33

Buchanan, W. Watson (coauthor) see **Rosenblum, David**, 228

Butfon, M.G. (coauthor) see **Beach, C.L.**, 450; see **Green, Jeffrey A.**, 450

Bugos, David W. (coauthor) see **Zeisler, John A.**, 207

Bulima nervosa, treatment (LA) 815

Bumetanide, adverse effects (NDE) 792; availability and cost (NDE) 795; chemistry (NDE) 786; clinical trials (NDE) 790; dosage and administration (NDE) 794; drug interactions (NDE) 794; evaluation (NDE) 786; mechanism of action (NDE) 786; new loop diuretic (NDE) 786; pharmacodynamics (NDE) 789; pharmacokinetics (NDE) 787

Bunegin, L. (coauthor) see **Watson, W.A.**, 441

Bupivacaine, anesthesiology (CTF) 760

Buprenorphine, comparative effects and analgesic efficacy (DSP) 411

Burckart, Gilbert J. (author) Cyclosporine A Blood Concentrations in a Child After Intravenous and Oral Therapy (ab) 446; (coauthor) see **Venkataramanan, R.**, 446

Burda, Anthony (coauthor) see **Stein, Z.L.G.**, 376

Burke, Wayne S. (author) book review, 145; (coauthor) see **Matzke, Gary R.**, 425

Burney, Jr., Dwight W. (coauthor) see **Cady, William J.**, 645

Bush, Patricia J. (author) Comment on Drugs, Alcohol, and Sex Review (L) 293

Busquet, Leandre (coauthor) see **Mas, Xavier**, 378

Bussay, Henry L. (author) Influence of Rifampin on Quinidine and Digoxin (ab) 436

Butorphanol, comparative effects and analgesic efficacy (DSP) 411

C

Cady, William J. (author) Ceforanide vs. Cephalothin Concentrations in Total Joint Arthroplasty (RPR) 645; (coauthor) see **Bryant, P.J.**, 445

Caffeine, adverse reactions, discussion of (CTF) 674; toxicity (CTF) 64

Calcitonin, treatment of hypercalcemia (A) 18

Calcium antagonists, adverse reactions, rebound angina (CTF) 592; pulmonary disease (CTF) 384

Calculators, programmable, comment (L) 48, dosage, phenytoin procedure (A) 890

Calvert, Jon C. (coauthor) see **Seaman, John J.**, 248; (coeditor) see **Longe, R. Leon**, 248

Cambridge diet, update (WNC) 398

Camphorated oil, removed from market (WNC) 78

Canada, Jr., Andrew T. (author) Amiodarone for Tachyarrhythmias: Pharmacology, Kinetics, and Efficacy (A) 100; (author) book review, 228

Cancer, chemotherapy see also **Antineoplastic agents**; adverse reactions, acute pancreatitis (CTF) 64; update of hexamethylmelamine and pentamethylmelamine (A) 418

Capella, Dolores (coauthor) see **Mas, Xavier**, 378

Captopril, cardiovascular disease (CTF) 139, 383; interactions, cimetidine (A) 114

Caranassos, G. (coauthor) see **Bendayan, R.**, 435

Carbamazepine, adverse reactions, bizarre behavior (CTF) 304; hyponatremia (CTF) 592; pseudo-toxic-shock syndrome (CTF) 925; cholesterol, serum concentration correlation (A) 812; interactions, erythromycin (DIR) 106, isoniazid (CTF) 224, theophylline (CTF) 475; neurology (CTF) 924; pharmacokinetics (A) 812; protein binding, geriatric population (ab) 438; thrombocytopenia, rash and hepatic dysfunction (CR) 642

Carbenicillin, infectious disease (CTF) 474

Cardiovascular Disease (CTF), albuterol 302; antiarrhythmics, 591; aspirin, 62, 924; captopril, 139, 383; clonidine, 474; diltiazem, 62; diltiazem, 924; flecainide, 673; gemfibrozil, 850; heparin, 850; hydrochlorothiazide, 140; magnesium sulfate, 760; metoprolol, 474; nifedipine, 140, 222,

- 302, 383; pindolol, 63; prazosin, 474, 760; prostaglandin E₂, 850; streptokinase, 222, 303; tocainide, 924; verapamil, 140, 223, 591, 850
- Cardoni, Alex A.** (author) Antidepressants and Dental Caries (DIAS) 810; (coeditor) see Jackson, Eric A., 7
- Carlin, Herbert S.** (author) VIP (WNC) 607
- Carroll, Norman V.** (author) The Relationship Between Patient Variables and Frequency of Pharmacist Counseling (RPR) 648
- Carson, Herbert B.** (author) Antibiotic Penetration in Abdominal Infection: A Case of Tobramycin Failure Responsive to Moxalactam (CTF) 277
- Carter, Barry L.** (author) Labetalol (NDE) 704; (author) Prediction of Maintenance Warfarin Dosage from Initial Patient Response (A) 23
- Case reports see Clinical Pharmacy Case Reports**
- Cefaclor**, decreased absorption in short bowel syndrome (CTC) 201
- Cefmenoxime**, clinical summary (A) 618; penetration into bile, cerebrospinal fluid, sputum, and other sites (ab) 433; pharmacokinetics (A) 509
- Cefeprozime**, clinical summary (A) 618; clinical use (NDE) 9; dosage and administration (NDE) 10; evaluation (NDE) 7; infectious disease (CTF) 591, 760; microbiology (NDE) 8; new drug evaluation (NDE) 7; pharmacokinetics (NDE) 8, (A) 509; pharmacology (NDE) 7; side effects and adverse reactions (NDE) 10
- Cefazolin**, clinical summary (A) 618; concentrations in total joint arthroplasty (RPR) 645; pharmacokinetics (A) 509
- Cefotaxime**, clinical summary (A) 618; infectious disease (CTF) 140, 223; neutropenia (CR) 739; pharmacokinetics (A) 511
- Cefotiam**, clinical summary (A) 618; pharmacokinetics (A) 509
- Cefoxitin**, adverse reactions, hemolytic anemia and pancytopenia (CR) 816
- Cefsulodin**, clinical summary (A) 619; efficacy and pharmacokinetics of combination with tobramycin in cystic fibrosis patients (ab) 446
- Ceftazidime**, clinical summary (A) 619; pharmacokinetics (ab) 444, (A) 511; pharmacokinetics during continuous ambulatory peritoneal dialysis and intermittent peritoneal dialysis (ab) 453
- Cefizoxime**, clinical summary (A) 619; pharmacokinetics (A) 512
- Ceftiraxone**, clinical summary (A) 619; infectious disease (CTF) 924; (RPR) 761
- Cefuroxime**, clinical summary (A) 618; pediatrics (CTF) 223; pharmacokinetics (A) 509
- Cephalexin**, pharmacokinetics in cystic fibrosis (ab) 439
- Cephalosporins**, see also all drugs by individual names; **cefeprozime** review (NDE) 7; **intravenous therapy** (CTF) 383; **side effect profiles**, newer generation (E) 656; **third generation**, and investigation, microbiologic review and clinical summaries (A) 615, review of cefeprozime (NDE) 7, structure-activity relationships and pharmacokinetic review (A) 507
- Cephalothin**, concentrations in total joint arthroplasty (RPR) 645
- Cerra, Frank B.** (coauthor) see Ackerman, Bruce, 433; see Elenbaas, Robert M., 722
- Chan, Marianne** (author) Lithium-Amiloride Interaction (DIAS) 809
- Chandrasekar, P.** (coauthor) see Smith, B.R., 433
- Charkowski, D.M.** (coauthor) see Leff, Richard D., 448
- Charles, Bruce G.** (coauthor) see Cordingley, Frank S., 467
- Chatterji, D.C.** (coauthor) see Pascucci, V.L., 447
- Chemotherapeutic agents**, oncology (CTF) 140
- Chen, Tai Wai David** (author) Effect of Probenecid on the Pharmacokinetics of Aminophylline (RPR) 465
- Chenodiol**, approved for gallstones (WNC) 747; gallstone dissolution (LA) 302
- Chen, Gilbert S.** (author) Prevention of Giardia in Drinking Water (DIAS) 344
- Chloramphenicol**, changing serum concentrations during therapy (ab) 452
- Chlordiazepoxide**, interactions, levodopa (DIR) 106
- Chlorophyllin**, effect on urinary odor, incontinent geriatric patients (G) 732
- Chloroquine**, interactions, plastics (DIR) 729
- Chlorpropamide**, hyponatremia (A) 175; overdose treated with diazoxide (CR) 372
- Chlorothalidone**, hypercalcemia (A) 180
- Cholesterol**, serum concentration correlation with carbamazepine (A) 812
- Cholestyramine**, treatment of digitoxin toxicity (CR) 57
- Choline magnesium trisulfate**, rheumatology (CTF) 224
- Choline theophyllinate**, dosage regimen (L) 133
- Chow, Belle L.** (author) Topical Acyclovir in Recurrent Herpes Infection (DIAS) 809
- Chow, Moses S.S.** (author) Pharmacokinetic Analysis of Seven Methods of Estimating Unstable Renal Creatinine Clearance (ab) 447; (coauthor) see Voelker, M.S., 447
- Chrischilles, Elizabeth A.** (author) Cost-Effectiveness of a Medication Refill Reminder System (ab) 441
- Christoff, Patricia B.** (author) Procanamide Disposition in Obesity (A) 516
- Chubb, J.M.** (coauthor) see Comstock, T.J., 453; see Straughn, Arthur B., 451
- Chymopain**, approved (WNC) 317; neurology (CTF) 760
- Cimetidine**, adverse reactions, activation of immune system (CTF) 384, impotence, breast tenderness, gynecostasia (CTF) 592, mania exacerbation (CTF) 925, thrombocytopenia (CR) 126; **anesthesiology** (CTF) 924; **gastroenterology** (CTF) 760; **general medicine** (CTF) 673; **interactions**, antacids (A) 114, (ab) 439, antibiotics (A) 113, antihistamines (A) 114, aspirin (A) 114, benzodiazepines (A) 111, beta-blockers (A) 112, captopril (A) 114, diet and dietary supplements (A) 113, glucose/insulin (A) 114, ketoconazole (A) 115, lidocaine (A) 113, (DIR) 108, metoclopramide (A) 114, morphine (A) 113, nortriptyline (CR) 904, oral pancreatic enzyme replacement therapy (A) 113, phenobarbital (A) 114, phenytoin (A) 111, procainamide (CTF) 141, propranolol (CTF) 384, theophylline (A) 111; **lack of interaction** lidocaine, suspected myocardial infarction (ab) 445; **multiple-dose effect** indocyanine green clearance (ab) 454; **potentiation** narcotic action (CR) 60; **resistance**, (DIAS) 629; **review**, drug interactions (A) 110; **toxicology** (CTF) 141
- Cinoxacin**, urology (CTF) 64
- Cisplatin**, adverse reactions, hearing loss (CTF) 475, optic disc swelling and loss of tendon reflexes (CTF) 224; **hypomagnesemia** (A) 181; **oncology** (CTF) 761; **urology** (CTF) 141
- Clark, John E.** (author) Cardiac Arrhythmias After Phenylpropanolamine Ingestion (CR) 737
- Clark, R.V.** (coauthor) see Pascucci, V.L., 447
- Clayton, Bruce D.** (author) book review, 852
- Clementi, W.A.** (coauthor) see Beach, C.L., 450, see Ebert, S.C., 451, see Farringer, J.A., 450, see Green, Jeffrey A., 370, 450, see Watson, W.A., 441
- Clindamycin**, infectious disease (CTF) 303, 673
- Clinical evaluations**, basis for drug product selection to hospital pharmacy formularies (ab) 450
- Clinical laboratories**, must lab directors be physicians (WNC) 237
- Clinical Pharmacy Case Reports**, A Mild Case of Toxic Shock Syndrome, 283; A Suspected Case of Codeine-Induced Erythema Multiforme, 128; Acute Overdose of Bromocriptine, 374; Acute Toxicity of Nonsteroidal Antiinflammatory Agents: Seizure Following a Mefenamic Acid Overdose, 204; Allergic Reaction to Purified Pork Insulin, 818; Antibiotic Penetration in Abdominal Infection: A Case of Tobramycin Failure Responsive to Moxalactam, 277; Carbamazepine-Induced Thrombocytopenia, Rash, and Hepatic Dysfunction, 642; Cardiac Arrhythmias After Phenylpropanolamine Ingestion, 737; Cholestyramine Resin in the Treatment of Digoxin Toxicity, 57; Cimetidine Potentiation of Narcotic Action, 60; Cimetidine-Associated Thrombocytopenia, 126; Cimetidine's Effect on Steady-State Serum Nortriptyline Concentrations, 904; Cisplatin-Induced Bradycardia, 899; Decrease in Theophylline Clearance After the Administration of Erythromycin to a Patient with Obstructive Lung Disease, 370; Decreased Absorption of Cefaclor in Short Bowel Syndrome, 201; Dose-Dependent Theophylline Elimination in an Adult, 202; Effect of Brand on the Serum Level of Aspirin, 550; Falsely Elevated Aminoglycoside Serum Levels in Jaundiced Patients, 544; Familial Warfarin Resistance, 281; Hemolytic Anemia and Pancytopenia Induced by Cefoxitin, 816; High-Dose Procainamide in Chronic Renal Failure, 279; Hypoprothrombinemia in Naproxen Overdose, 549; Neutropenia Associated with Cefotaxime, 739; Parenteral Nutrition in a Patient With Familial Type IV Hypertriglyceridemia: A Dilemma, 458; Phenytoin-Induced Lymphadenopathy, 460; Primidone-Induced Cataplexy Schizophrenia, 551; Prolonged Diarrhea Secondary to Methylgluta Therapy, 462; Quinidine Interaction with Anticonvulsants, 819; Recurrence of Intravenous Diazepam-Induced Phlebitis from Oral Diazepam, 125; Scotomas Secondary to Digoxin Intoxication, 368; Spiking Fever Induced by Isoniazid, 741; The Effects of Exchange Transfusion on the Pharmacokinetics of Phenobarbital, 901; Theophylline Toxicity—A Consequence of Congestive Heart Failure, 59; Topical Sclerotherapy of Oropharyngeal Varices, 640; Transient Asystole Associated with Amphotericin B Infusion, 547; Treatment of Chlorpropamide Overdose with Diazoxide, 372; Treatment of L-asparaginase Allergic Reaction, 130; Tricyclic-Induced Seizure Activity, 644; Use of Dimenhydrinate in the Treatment of Green Tobacco Sickness, 548; Zomepirac-Related Acute Renal Failure, 56
- Clinical Research** see also **Research; informed consent**, requirements (A) 828; **institutional review board**, policies (A) 831, role of (A) 828, protocol guidelines (A) 833
- Clinical trials**, unique design, investigational drugs single dose-dose response profile, (ab) 445
- Clomethiazole**, interactions, plastics (DIR) 729
- Clomiphen**, neurology (CTF) 303
- Clonidine**, cardiovascular disease (CTF) 474; overdose in children, therapeutic nonintervention, safety and efficacy (ab) 451; psychiatry (CTF) 592; suppression test for pheochromocytoma (DIAS) 719
- Closson, Richard G.** (author) Comment on Kinetic Predictions of Serum Drug Concentrations (L) 653; Drug Treatment of Drug-Induced Seizures (ab) 449
- Clotrimazole**, obstetrics/gynecology (CTF) 924
- Co-trimoxazole**, infectious disease (CTF) 850
- Cocaine**, obstetrics/gynecology (CTF) 761
- Codeine**, adverse reactions, erythema multiforme (CR) 128
- Coelho, A.** (coauthor) see Bauman, Jerry L., 435; see Hoff, J.V., 440
- Coenzyme Q-10**, results of cardiac study (WNC) 317
- Cohen, Albert** (coauthor) see Strathman, Irvin, 635
- Colchicine**, hypocalcemia (A) 180; rheumatology (CTF) 304
- Colistin**, update on ototoxicity (L) 48
- Collie, Karen L.** (coauthor) see Ward, Thomas T., 552
- Collier, Paul S.** (author) Programmed Solution for the Michaelis-Menten Equation (L) 559
- Color additives**, FD&C Blue No. 2 (WNC) 154; update (WNC) 318
- Computers**, drug therapy for epilepsy (RPR) 123; microcomputer program for tobramycin consult services (A) 528
- Comstock, T.J.** (author) Cefazidime Pharmacokinetics During Continuous Ambulatory Peritoneal Dialysis and Intermittent Peritoneal Dialysis (ab) 453
- Congestive heart failure**, theophylline toxicity (CR) 59; theophylline clearance, obese patients (A) 274
- Coniglio, A.A.** (coauthor) see Senholdt, Craig S., 445
- Conjunctivitis**, prophylaxis, neonates (LA) 139
- Conner, Christopher S.** (author) Literature Analysis: Azlocillin, 222, Efficacy and Safety of Nicotine Gum, 62, Indapamide: A Unique Diuretic, 898, Intravenous Streptokinase in Acute Myocardial Infarction, 367, Labetalol: An Alpha- and Beta-Blocker, 543, Nifedipine: Two New Uses, 457, Prophylaxis of Neonatal Conjunctivitis, 139, Sleep Apnea, 736, Therapy of Syndrome Malin, 639, Treatment of Bulimia, 815, Ursodeoxycholic Acid: Superior to Chenodiol, 302; (coeditor) see Sawyer, Dennis R., 383; (editor) Current Therapeutic Findings, 62, 139, 222, 302
- Conrad, Kenneth A.** (coauthor) see Mayersohn, Michael, 131
- Contact lenses**, interactions, drugs (DIR) 730; reclassification (WNC) 239
- Conse, R.R.** (author) Pharmacists as Primary Care Providers (ab) 442
- Conti, David R.** (coauthor) see Christoff, Patricia B., 516
- Continuing education** see **PharmACE test questions**, 75, 150, 235, 312, 395, 482, 603, 685, 772, 860, 938
- Contraceptives**, sponge approved (WNC) 485
- Cooper, James W.** (coauthor) see Wiederhold, Joseph B., 216
- Cordingley, Frank S.** (author) More Convenient Use of NONLIN (L) 467
- Correa, Sandra P.** (coauthor) see Graves, Terri, 130
- Corrections** see Letters, 50, 294, 469, 655, 849
- Corticosteroids**, associated with avascular bone necrosis (DIAS) 343; use in septic shock (CR) 97
- Corticosteroids**, gastroenterology (CTF) 924
- Coumarin**, interactions, acetaminophen (DIR) 108
- Covington, Timothy R.** (author) Toward a Rational Approach to the Issue of Prescribing Authority for Pharmacists (O) 660
- Crawford, M.H.** (coauthor) see Beach, C.L., 450
- Cresciani**, clearance, pharmacokinetic analysis, methods of estimation (ab) 447
- Creeger, Richard J.** (author) Dose-Dependent Theophylline Elimination in an Adult (CR) 202
- Critical care panel**, bibliography, 722
- Critical Care Therapeutics**, Management of Septic Shock, 92; Nutritional Support of the Critically Ill Patient, 501; Therapeutic Bibliography of Critical Care, 722
- Crom, William R.** (author) Doxorubicin Disposition in Children and Adolescents with Cancer (ab) 448; (coauthor) see Stewart, C.F., 448
- Cross, R.E.** (coauthor) see Powell, J. Robert, 445
- Cutaneous, Pedro** (author) Developing Concepts in Receptor Research (A) 357
- Culbertson, V.L.** (coauthor) see Bryant, P.J., 445
- Cupit, Gary C.** (author) Clonidine Overdose in Children: Safety and Efficacy of Therapeutic Nonintervention (ab) 451
- Current Therapeutic Findings**, 62, 139, 222, 302, 383, 474, 591, 673, 760, 850, 924
- Curry, R. Whit, Jr.** (coauthor) see Quattrocchi, Frank P., 286
- Curry, Stephen H.** (coauthor) see Darzentas, Lazarus J., 555
- Curtis, Robert A.** (author) Predictability of Theophylline Concentrations in Patients with Acute Exacerbations of Obstructive Airway Disease (ab) 443; (coauthor) see Elenbaas, Robert M., 722; (coauthor) see Giacomini, Nicola, 452; (coauthor) see Searcy, C.J., 452; (coauthor) see Zell, Michele, 442
- Cwik, M.** (coauthor) see Giacomini, Nicola, 452
- Cycloclacin**, pediatrics (CTF) 223
- Cyclophosphamide**, rheumatology (CTF) 141; water retention (A) 175
- Cyclosporine**, blood levels, iv (ab) 446, oral (ab) 446, (ab) 451; **endocrinology** (CTF) 760; **FDA approval** (WNC) 862; **ophthalmology** (CTF) 925; **removal**, hemodialysis (ab) 446

D

- D-penicillamine** see **Penicillamine**
- D'Agostino, Joseph** (coauthor) see Jochsberger, Theodore, 551, 849
- D'Arcy, P.F.** (author) Drug Interactions and Reactions Update: Drug Interactions with Medical Plastics, 726, Early Reports on Drug Interactions, 105; Reactions and Interactions in Handling Anticancer Drugs (A) 532
- Dahl, Stephen L.** (author) Lack of Correlation Between Blood Gold Levels and Clinical Response in Patients with Definite or Classical Rheumatoid Arthritis on Two Forms of Gold Therapy (ab), 449
- Dahlia, Patricia A.** (author) Views of Pharmacy Supportive Personnel in Florida (A) 576
- Dalkon Shield**, pelvic inflammatory disease, elevated risk (WNC) 607
- Daneck, Adam** (author) book review, 679
- Dantrolene**, neuroleptic malignant syndrome, treatment (LA) 639; neurology (CTF) 673
- Dapsone**, dermatitis herpetiformis (ab) 434; toxicology (CTF) 925
- Darzentas, Lazarus J.** (author) Effect of Antacid on Bioavailability of a Sustained-Release Theophylline Preparation (RPR) 555
- Dasta, Joseph F.** (coauthor) see Armstrong, D., 437; (editor) Critical Care Therapeutics, 92, 501, 722
- Data collection**, drug information, obtaining from pharmaceutical manufacturers (A) 27; education, fellowships, 1983-84 survey (A) 835; salaries, fellowships, 1983-84 survey (A) 835

- Davidson, Karen H. (author) book review, 229
- Davis, C.M. (coauthor) see Ereshefsky, Larry, 436
- Davis, Harry L. (coauthor) see Henderson, Robert P., 741
- Davis, Larry Jay (coeditor) see Hart, Linda L., 186
- Davis, R. (coauthor) see Bauer, L.A., 434
- Davis, T. (coauthor) see Seifert, Randall D., 451
- Degg, H.J. (coauthor) see Yee, Gary C., 451
- Deferoxamine, retinal toxicity (CTF) 925
- Delafuente, Jeffrey C. (author) Influence of Age and Disease State on Delayed Cutaneous Hypersensitivity (ab) 433
- Delaney, John P. (coauthor) see Mann, Henry J., 126
- Delta-9-tetrahydrocannabinol, ophthalmology (CTF) 592
- Demethyl chlorzacycline, associated with water loss (A) 177
- DeMonaco, Harold J. (author) Transient Aystole Associated with Amphotericin B Infusion (CR) 547
- DeNicola, Romulus L. VIP (WNC), 941
- Derelugation, dangers (E) 320
- Dermatology (CTF), benoxaprofen, 924; dexamethasone, 673; evening primrose seed oil (efamol) 303; fluorouracil, 223; ketoconazole, 63, 140, 383, 673; metronidazole, 591; nitroglycerin, 424; primidone, 850; sodium hypochlorite, 474; triamcinolone acetonide, 850; trimethoprim, 223; vitamin E, 760
- Dermatology panel, isotretinoin evaluation (NDE) 329
- DeTorres, Olga H. (author) Hemolytic Anemia and Pancytopenia Induced by Cefotaxime (CR) 816
- DeVane, C. Lindsay (author) Use of Psychoactive Drugs in Children (E) 562
- Dexamethasone, dermatology (CTF) 673; oncology (CTF) 850; suppression test, psychiatry (CTF) 475
- Diabetes, anesthesiology (CTF) 139; endocrinology (CTF) 760; management of children, behavior modification and blood glucose monitoring (ab) 438
- DIAS Rounds, Adverse Reactions with Diazepam, 630; Antidepressants and Dental Caries, 810; Calcium Channel Blockers in Premature Labor, 808; Clonidine Suppression Test, 719; Enhancement of Tricyclic Antidepressants by Thyroid, 718; Equivalence of Levotyrosine Tablets, 265; Giardiasis and Amebiasis in Pregnancy, 187; Intrathecal Morphine, 720; Intrathecal Sodium Fluorescein, 186; Lithium-Amiloride Interaction, 809; Lysine for Herpes Simplex Virus, 186; Metoclopramide in Patients with Renal Failure, 264; Prevention and Treatment of Traveler's Diarrhea, 265; Prevention of Giardiasis in Drinking Water, 344; Ranitidine in Cimetidine-Resistant Ulcers, 629; Rash Due to Erythromycin, 631; Steroid Pulse Therapy in Systemic Lupus Erythematosus, 342; Steroids and Avascular Bone Necrosis, 343; Topical Acyclovir in Recurrent Herpes Infection, 809
- Diazepam, adverse reactions (DIAS) 630, phlebitis (CR) 125, spasmodic torticollis (CTF) 674; interactions, plastics (DIR) 728, ranitidine (CTF) 761; neurology (CTF) 591; psychiatry (CTF) 925; use tardive dyskinesia (A) 523
- Diazoxide, cardiovascular disease (CTF) 62; treatment of chlorpropamide overdose (CR) 372
- DICP see Drug Intelligence and Clinical Pharmacy
- Diet and dietary supplements, interactions, cimetidine (A) 113
- Diffunisal, general medicine (CTF) 223
- Digoxin, toxicity, cholestyramine resin, treatment (CR) 57
- Digoxin, absorption, small bowel resections (RPR) 121; amiodarone, effect, suppression of red blood cell uptake in vitro (ab) 445; determining dose, comparison of two lean body weight formulas elderly (ab) 454; ibuprofen, effect, serum concentrations (RPR) 286; metoprolol, effect, disposition (ab) 443; interactions, amiodarone (A) 103, nifedipine (CTF) 224, quinidine (CTF) 64; rifampin, influence (ab) 436; scotomas, secondary to intoxication (CR) 368; serum concentrations, predictability (RPR) 821; toxicology, specific lab antibody fragments (CTF) 224
- Diliazem, cardiovascular disease (CTF) 924
- Dimenhydrinate, green tobacco sickness (CR) 548
- Dimethyl sulfoxide, adverse reactions, partial thickness burn (CTF) 761; interactions, sulindac (CTF) 851; oncology (CTF) 761; rheumatology (CTF) 224
- Dionne, Roger E. (author) Pirofen (ID) 894
- Disopyramide phosphate, adverse reactions, hypoglycemia and lactic acidosis (CTF) 475; hypoglycemia, postmarketing drug surveillance (A) 635; interactions, phenytoin (CTF) 64; pediatrics (CTF) 140
- Dispensing, legal issues, dosage units dispensed (F) 756
- Disulfiram/calcium carbimide, interactions, ethanol (CTF) 851
- DNA products, FDA regulating recombinant products (WNC) 31
- Dobbs, J.H. (author) Cost-Effectiveness of a Clinical Pharmacist as a Provider of Mental Health Care (ab) 433
- Dobutamine, pediatrics (CTF) 851; use in septic shock (CC) 96
- Docusate sodium, acceleration of peritoneal dialysis (ab) 440
- Doering, Paul L. (author) book review, 679; (author) Clinical Pharmacy: Two Steps Forward, One Step Back (O) 564; (coauthor) see Russell, W.L., 439
- Dolan, Margaret M. (coauthor) see Saltzman, Marcus B., 746
- Dolly, F.R. (coauthor) see Gots, Vincent P., 434
- Doluisio, James, VIP (WNC) 607
- Dominguez, Andres E. (coauthor) see Taketomo, Robert T., 821
- Domperidone, gastroenterology (CTF) 303
- Donaldson, Elvis S. (coauthor) see Rapp, Robert P., 458
- Donati-Cori, Giancarlo (coauthor) see Messori, Andrea, 290, 890
- Donn, K.H. (author) Indocyanine Green Pharmacokinetics: Comparison of Spectrophotometric and High Pressure Liquid Chromatographic Analytical Methods in Humans (ab) 446
- Dopamine, use in septic shock (CC) 96
- Dorevitch, Abraham (author) Comment on Maprotiline Article (L) 559
- Dorr, Robert T. (author) book review, 387
- Doutre, William H. (coauthor) see Guernsey, Brock G., 742, 754
- Doxorubicin, disposition, children and adolescents with cancer (ab) 448; oncology (CTF) 140
- Doxylicline, traveler's diarrhea (DIAS) 266
- Doxylamine-pyridoxine, combination, see Bendectin
- Doyle, Nancy (coauthor) see Saltzman, Marcus B., 746
- Dozier, Nicky (author) Acquired Immune Deficiency Syndrome and the Management of Associated Opportunistic Infections (A) 798
- Drug abuse, elderly (E) 657
- Drug administration, intravenous, infusions, overfill effects (L) 847
- Drug evaluations see Drug Selection Perspectives; Investigational Drug Information; Literature Analysis; New Drug Evaluations
- Drug information, addendum to listing (L) 654; corrections to listing (L) 913; obtaining from pharmaceutical manufacturers (A) 27; patient education (WNC) 154
- Drug Information Analysis Service see DIAS Rounds
- Drug Intelligence and Clinical Pharmacy, abstracted and indexed, 2, 82, 162, 244, 322, 402, 490, 610, 698, 778, 869; advertising inquiries, 1, 81, 161, 243, 321, 401, 489, 609, 697, 777, 868; announcements, American College of Clinical Pharmacy, Fifth Annual Meeting 1984 Call for Papers, 759, 854, 913, Fourth Annual Meeting Call for Abstracts, 74, Joint Program with Academy of Pharmaceutical Sciences, 676, Southwest Conference, 215; American Society of Hospital Pharmacists, Call for Papers, 389, IPA, 614, 702, 958; Association of Pharmacy Technicians, First National Convention, 596; Cancer Chemotherapy Fifth Annual Pharmacy Symposium, 522; Eighth Institute on Drugs, Crime, and Justice in England and America, 142, 230; European Symposium on Clinical Pharmacy, 294, 309; Institute for the Clinical Application of Pharmacokinetics, Three-Day Intensive Training, 622; Lisbon, First Symposium on Clinical Pharmacy, 387, 522, 622, 767, 846; National Experts to Teach Pharmacokinetics Course, 731; Ohio Conference on Clinical Pharmacy and Clinical Pharmacology, Third Annual, 594; Phi Delta Chi Centennial and Alumni Brothers Search, 345; Polish Pharmacological Society 8th Congress, 473; Spanish Society of Hospital Pharmacists, National Conference, 515; University of Rochester, Annual Postgraduate Clinical Pharmacology Course, 387; author guidelines, 81, 161, 243, 321, 401, 489, 609, 697, 777, 868; back issues, availability, 138, 712, 825; bound volumes, 221, 305, 341, 488, 515, 933; bound volume special offer (Se, Oc, No) ibc, 957; change of address notification, 81, 161, 243, 321, 401, 489, 609, 697, 777, 868; column editors, 2, 82, 162, 244, 322, 402, 490, 610, 698, 778, 869; continuing education program description, 2, 47, 82, 162, 230, 314, 322, 385, 403, 612, 768, (J/A) ibc, program tests, 75, 150, 235, 312, 395, 482, 603, 685, 772, 850, 938; editorial council and panels (Ja, Fe, Mr, Ma, Je, J/A, Se, Oc, No) ibc, (De) ibc, 245; education consultants, 2, 82, 162, 314, 322, 403, 609, 672, 768, 811, 897; indexed and abstracted, 2, 82, 162, 244, 322, 402, 490, 610, 698, 778, 869; management and purpose, 1, 81, 161, 243, 321, 401, 489, 609, 697, 777, 868; PharmACE description, 2, 47, 82, 162, 230, 314, 322, 385, 403, 612, 768, (J/A) ibc; program application form, 47, 230, 314, 385, 403, 612, 768, (J/A) ibc, tests, 75, 150, 235, 312, 395, 482, 603, 685, 772, 850, 938; referees, appreciation, 944; reprint information, 221, 341, 401, 488, 489, 609, 697, 777; subscription information (Ja, Fe, Mr, Ap, Ma, Je, J/A, Se, Oc, No, De) ibc; subscription rates, 1, 81, 161, 243, 321, 401, 489, 609, 697, 777, 868; subscription and bound volume special offer (Se, Oc, No) ibc, 957; subscription and book offer, 780
- Drug interactions, acetaminophen-coumarin (DIR) 108 amiloride-lithium (DIAS) 809 aminoglycosides-cephalosporins (RPR) 906 aminoglycosides-penicillins (RPR) 906 amiodarone-digoxin (A) 103 amiodarone-quinidine (DIR) 105 amiodarone-warfarin (A) 103 antacids-cimetidine (A) 114 antibiotics-cimetidine (A) 113 anticonvulsants-quinidine (CR) 819 antihistamines-cimetidine (A) 114 aspirin-cimetidine (A) 114 aspirin-ethanol (DIR) 107 azapropazone-phenytoin (DIR) 106 benzodiazepines-cimetidine (A) 111 beta-blockers-cimetidine (A) 112 captopril-cimetidine (A) 114 carbamazepine-erythromycin (DIR) 106 cephalosporins-aminoglycosides (RPR) 906 chlorzacycline-levodopa (DIR) 106 chlorzacycline-plastics (DIR) 728 cimetidine-antacids (A) 114 cimetidine-antibiotics (A) 113 cimetidine-antihistamines (A) 114 cimetidine-aspirin (A) 114 cimetidine-benzodiazepines (A) 111 cimetidine-beta-blockers (A) 112 cimetidine-captopril (A) 114 cimetidine-diet and dietary supplements (A) 113 cimetidine-glucose/insulin (A) 114 cimetidine-ketoconazole (A) 115 cimetidine-lidocaine (A) 113 cimetidine-lidocaine (DIR) 108 cimetidine-metoclopramide (A) 114 cimetidine-morphine (A) 113 cimetidine-nortriptyline (CR) 904 cimetidine-pancreatic enzyme replacement (A) 113 cimetidine-phenobarbital (A) 114 cimetidine-phenytoin (A) 111 cimetidine-propantheline (A) 114 cimetidine-theophylline (A) 111 cimetidine-theophylline (DIR) 729 coumarin-acetaminophen (DIR) 108 11-creatinine (RPR) 908 diazepam-plastics (DIR) 728 diet and dietary supplements-cimetidine (A) 113 digoxin-amiodarone (A) 103 erythromycin-carbamazepine (DIR) 106 ethanol-aspirin (DIR) 107 furosemide-gentamicin (DIR) 107 gentamicin-furosemide (DIR) 107 glucose/insulin-cimetidine (A) 114 insulin-plastics (DIR) 726 isorbide-plastics (DIR) 729 ketoconazole-cimetidine (A) 115 levodopa-chlorzacycline (DIR) 106 lidocaine-cimetidine (A) 113 lidocaine-cimetidine (DIR) 108 lidocaine-prenylamine (DIR) 106 lithium-amiloride (DIAS) 809 metoclopramide-cimetidine (A) 114 morphine-cimetidine (A) 113 nitroglycerin-plastics (DIR) 728 nortriptyline-cimetidine (CR) 904 pancreatic enzyme replacement-cimetidine (A) 113 penicillins-aminoglycosides (RPR) 906 phenobarbital-cimetidine (A) 114 phenytoin-azapropazone (DIR) 106 phenytoin-cimetidine (A) 111 plastics-chlorzacycline (DIR) 729 plastics-chlorzacycline (DIR) 729 plastics-diazepam (DIR) 728 plastics-insulin (DIR) 726 plastics-isorbide (DIR) 729 plastics-nitroglycerin (DIR) 728 plastics-vitamin A (DIR) 728 prenylamine-lidocaine (DIR) 106 propantheline-cimetidine (A) 114 quinidine-amiodarone (DIR) 105 quinidine-anticonvulsants (CR) 819 theophylline-cimetidine (A) 111 vitamin A-plastics (DIR) 728 warfarin-amiodarone (A) 103
- Drug Interactions (CTF), alcohol-moxalactam, 141 aminoglycosides-magnesium sulfate, 674 anticonvulsants-valproic acid, 384 aspirin-lithium, 592 benzodiazepines-oral contraceptives, 592 broccoli-warfarin, 761 carbamazepine-isoniazid, 224 carbamazepine-theophylline, 475 cimetidine-procainamide, 141 diazepam-ranitidine, 761 digoxin-nifedipine, 224 digoxin-quinidine, 64 dimethyl sulfoxide-sulindac, 851 disopyramide-phenytoin, 64 disulfiram/calcium carbimide-ethanol, 851 dyphylline-probenecid, 925 erythromycin-methylprednisolone, 925 ethanol-disulfiram/calcium carbimide, 851 ethanol-lorazepam, 592 ibuprofen-phenytoin, 304 iron preparations-ocult blood tests, 141 isoniazid-carbamazepine, 224 lithium-aspirin, 592 lorazepam-ethanol, 592 magnesium sulfate-aminoglycosides, 674 methylprednisolone-erythromycin, 925 metoprolol-ranitidine, 851 metronidazole-phenobarbital, 475 moxalactam-alcohol, 141 nifedipine-digoxin, 224 occult blood tests-iron preparations, 141 oral contraceptives-benzodiazepines, 592 perphenazine-tricyclic antidepressants, 304 phenobarbital-metronidazole, 475 phenytoin-disopyramide, 64 phenytoin-ibuprofen, 304 phenytoin-theophylline, 224 probenecid-dyphylline, 925 procainamide-cimetidine, 141 propranolol-ranitidine, 384 quinidine-digoxin, 64 ranitidine-metoprolol, 851 ranitidine-propranolol, 384 succralfate-warfarin, 674 sulfipyrazole-warfarin, 64 sulindac-dimethyl sulfoxide, 851 theophylline-carbamazepine, 475 theophylline-phenytoin, 224 tricyclic antidepressants-perphenazine, 304 valproic acid-anticonvulsants, 384 warfarin-broccoli, 761 warfarin-succralfate, 674 warfarin-sulfinpyrazole, 64
- Drug Interactions and Reactions Update, Drug Interactions with Medical Plastics, 726; Early Reports on Drug Interactions, 105; Reactions and Interactions in Handling Anticancer Drugs, 532
- Drug prescribing, unlabeled indications (WNC) 77
- Drug Selection Perspectives, Comparative Effects and Analgesic Efficacy of the Agonist-Antagonist Opioids, 411
- Drug testing, FDA to ease requirements (WNC) 397
- Drug therapy, written communications, between physicians (RPR) 288
- Drugs, advertising, see Advertising: FDA approval,

cyclosporine, (WNC), 862; recalls, Bendectin, comment on (E) 526

Drugs, Adverse Drug Reactions (CTF), acetaminophen, cirrhosis, 851, liver disease, 475; **acetylcysteine,** anaphylactic-type reaction, 224; **alfalfa,** exacerbation of systemic lupus erythematosus, 761; **alkylating agents,** acute nonlymphocytic leukemia, 304; **amlodrine,** decreased serum potassium, 384; **amniocentesis,** acute necrotic myopathy, 64; **amiodarone,** pulmonary toxicity, 304; **amitriptyline,** acute dystonic reaction, 141, malignant hypertension, 224; **amoxapine,** agranulocytosis, 925, akathisia and cogwheel rigidity, 384, tardive dyskinesia, 592; **antidepressants,** tricyclics and skin rashes, 64; **antithyroid drugs,** agranulocytosis, 384; **asparaginase,** hyperthermia, 674; **aspirin,** coronary artery spasms and angina, 592, submucosal hemorrhages, 384; **auranofin,** glomerulonephritis, 141; **baclofen,** convulsions, 64; **beta-blockers,** acute psychosis, 761, metabolic effects, 761, renal function, 304; **bromocriptine,** acute psychosis, 304; **caffeine,** discussion of adverse effects, 64; **calcium antagonists,** rebound angina, 592; **cancer chemotherapy,** acute pancreatitis, 64; **carbamazepine,** bizarre behavior, 304, hyponatremia, 592, pseudo-toxic-shock syndrome, 925; **cimetidine,** activation of immune system, 384, impotence, breast tenderness, gynecomastia, 592, mania, exacerbation, 925; **cisplatin,** hearing loss, 475, optic disc swelling and loss of tendon reflexes, 224; **diazepam,** spasmodic torticollis, 674; **deferaxamine,** retinal toxicity, 925; **dimethyl sulfoxide,** partial thickness burn, 761; **disopyramide,** hypoglycemia and lactic acidosis, 475; **electrolytes,** abnormalities, 141; **epinephrine,** cardiac dysfunction, 224; **erythromycin,** jaundice, 925; **haloperidol,** cholestatic liver disease, 64; **hydrochlorothiazide,** acute pulmonary edema, leukopenia and thrombocytopenia, 384; **ibuprofen,** no reaction, 925, cognitive dysfunction, 141; **ioctanide acid,** thrombocytopenia, 851; **isosorbide dinitrate,** hemolytic anemia, 475; **isotretinoin,** skeletal hyperostosis, 674; **ketoneconazole,** decreased testosterone concentrations, 384; **lithium,** lupus-like syndrome, 64, renal toxicity, 384, withdrawal effects, 925; **lomustine,** fatal pulmonary toxicity, 304; **methotrexate,** gynecomastia, 761, paronychia, 925; **methylodopa,** retroperitoneal fibrosis, 851; **metoclopramide,** acute dystonic reaction and respiratory failure, 851; **metronidazole,** grand mal seizures, coma, behavior abnormalities, 475; **moxalactam,** bleeding diathesis, 384, hypoprothrombinemia, hemorrhage, pseudomembranous colitis, fungal superinfection, 475; **naproxen,** cognitive dysfunction, 141, eosinophilic pneumonia, 475; **neomycin,** necrotizing enterocolitis, 384; **nifedipine,** pancreatitis, 674; **oral contraceptives,** effect on lipid levels, 592; **penicillamine,** cross-reactivity to skin test antigens, 851, cutaneous side effects, 592, systemic lupus erythematosus, 224; **phenylbutazone,** pericarditis, salivary gland enlargement and atrial fibrillation, 64; **phenylephrine,** no reaction, 141; **phenylpropanolamine,** acute renal failure and rhabdomyolysis, 64; **piroxicam,** no fecal blood loss, 64; **potassium chloride,** gastrointestinal lesions, 475; **prednisone,** behavioral disorders, 304; **propranolol,** depression, 141; **psoralen/UV light,** discussion of side effects, 674; **pyrimethamine,** component in Fansidar, Stevens-Johnson syndrome, 304; **ranitidine,** no effect on blood glucose or insulin, 224; **streptokinase,** Guillain-Barre syndrome, 674; **succalfate,** duodenal ulcer, 141; **sulfasalazine,** agranulocytosis, erythroid hypoplasia, plasmocytosis, 224, glandular fever-like illness, 224, systemic lupus erythematosus, 141; **sulfindac,** neutropenia complicated by pseudomonal septicemia, 224, renal toxicity, 304, splenomegaly, lymphadenopathy, 141; **tetanus toxoid,** anaphylactic reaction, 64; **tolmetin,** zomepirac, anaphylactoid reactions, 761; **trazodone,** ventricular arrhythmias, 851; **verapamil,** atrioventricular junctional rhythm, 384; **vitamin A,** hypercalcemia, 224; **zomepirac,** serum sickness, 761

Drugs, adverse reactions, acetate, letter to physicians (WNC) 862; amoxapine, neurotoxicity (L) 131; asparaginase, allergy (CR) 130; cefoxitin-induced hemolytic anemia and pancytopenia (CR) 816; cimetidine, thrombocytopenia (CR) 126; codeine, erythema multiforme (CR) 128; diazepam, phlebitis (CR) 125; insulin, allergy to purified pork (CR) 818; see also **Drug Interactions and Reactions Update**

Dubrow, I.W. (coauthor) see **Hedrick, P.J.**, 443

Duffy, J. Patrick (coauthor) see **Miller, Del D.**, 445, 904

Dufresne, Robert L. (coauthor) see **Weber, Stanley S.**, 523

Dunn, Judith K. (coauthor) see **Guernsey, Brock G.**, 754

Durrell, D.E. (coauthor) see **Nabata, Milap C.**, 439

Durst, N.L. (coauthor) see **Green, Jeffrey A.**, 450

E

Eaton, Margaret L. (coauthor) see **Rumsfeld, Jean A.**, 329

Ebert, S.C. (author) *In Vitro* Inactivation of Gentamicin by Carbenicillin Compared by Emit and Microbiological Assays (ab) 451

Editorials see also **An Opinion: Alexander, Michael R.**, Drug Deficiency States, 295; **Archambault, George F.**, Accolades to Dale E. Wurster, 942, A Potential Step Backward for Pharmacy, 864, Dangers in Deregulation, 320, How Effective Are the New Dosage Forms?, 486, Matters Mostly Associational in Nature, 690, The "Switch" is On, 155, The Legal Standard of Foreseeability as Applied to Legend-Drug-Product Tampering or Abuse, 400, The Orphan Drug Products-Another Solution?, 80, USAN and the USP Dictionary of Drug Names - Who Needs It? (E) 608;

Berman, Alex, It's a Bazaar, Then? No, It's a Drugstore!, 209; **DeVane, C. Lindsay,** Use of Psychoactive Drugs in Children, 562; **Gaglietta, Timothy S.,** Diarrhea: Some New Aspects of Pharmacotherapy, 914; **Hays, Dennis P.,** Bendectin: A Case of Mourning Sickness, 826; **Lamy, Peter P.,** Drug Abuse by Older Adults—Who is Responsible?, 657; **Moore, Robert,** Reporting Problems with Medical Devices, 240; **Nabata, Milap C.,** The Role of the Clinical Pharmacist: Need and Priority, 751; **Owen, John A., Jr.,** Vox Clamantis in Deserto, 776; **Prince, Randall A.,** Side-Effect Profiles of New-Generation Cephalosporins, 656; **Whitney, Jr., Harvey A.K.,** Let Us Now Praise Famous Men, 45

Edmunds, Marilyn W. (author) book review, 70

Education and Research News (WNC), University of Arizona receives grant, 940

Education, pharmaceutical, AACAP, denounces retroactive Pharm.D. degrees (WNC) 79; **fellowships,** 1983-84 survey (A) 835, stipends for fellows, survey of (A) 835; **1983 AACAP meeting,** comments by president George Zograf (WNC) 863

Eisenberg, J.D. (coauthor) see **DeLaunente, Jeffrey C.**, 433

Electrolytes, adverse reactions, abnormalities (CTF) 141; drug-induced disorders (A) 175

Elenbaas, Julia (author) Steroid Pulse Therapy in Systemic Lupus Erythematosus (DIAS) 342; (coauthor) see **Armstrong, Ed.**, 186, see **Lander, Roger**, 630

Elenbaas, Robert M. (author) Therapeutic Bibliography of Critical Care (CC) 722; (coauthor) see **Mueller, C.E.**, 440

Elias, S.B. (coauthor) see **Quandt, Christine M.**, 438

Elliott, Gary L. (author) Treatment of Hypercalcemia (A) 12

Elvin, A.T. (coauthor) see **Giacina, Nicola,** 452

Emergency services, drug-related problems in patients presenting to an emergency service are (ab) 449

Endocrinology (CTF), cyclosporine, 760; diabetes, 760; epinephrine, 474; insulin, 991; metoclopramide, 140; sodium valproate, 673

Ephedrine, anesthesiology (CTF) 222; endocrinology (CTF) 474; formulations for asthma (L) 653

Epilepsy, computer-assisted drug therapy (RPR) 123

Epinephrine, adverse reactions, cardiac dysfunction (CTF) 224; recall (WNC) 318

Epoprostenol, hematology (CTF) 383

Ereshesky, Larry (author) Pharmacokinetics of Fluiphenazine by High Performance Thin Layer Chromatography (ab) 436

Erkan, N.V. (coauthor) see **Gal, Peter,** 434

Erythema multiforme, codeine-induced (CR) 128

Erythromycin clearance, decrease in theophylline (CR) 370; interactions, carbamazepine (DIR) 106, warfarin (ab) 438; jaundice (CTF) 925; prophylaxis, neonatal conjunctivitis (LA) 339; rash (DIAS) 631

Esbridge, Roger A. (author) The Management of Septic Shock (CC) 92

Esophageal varices, topical sclerotherapy (CR) 640

Estrogens, hypercalcemia (A) 180

Ethanol, interactions, aspirin (DIR) 107, disulfiram/calcium carbimide (CTF) 851, lorazepam (CTF) 592

Ethylene glycol, toxicity and treatment (L) 376

Etomidate, anesthesiology (CTF) 850

Etoposide, oncology (CTF) 592; pharmacokinetics in children with refractory solid tumors (ab) 442

Evans, R. (coauthor) see **Lau, Alan,** 436

Evans, William E. (coauthor) see **Crom, William R.**, 448, see **Hutson, Paul R.**, 442, see **Stewart, C.F.**, 448

Evening Primrose Seed Oil, dermatology (CTF) 303; rheumatology (CTF) 925

Extravasation, a hazard of intravenous therapy (A) 713

F

Fabri, Peter J. (coauthor) see **Miralto, Jay M.**, 434

Farringer, J.A. (author) Electrocardiographic Effects and Time Course of the Phenytoin and Quinidine Interactions (ab) 450; (author) Relationship Between N-Acetylprocainamide Serum Concentrations and Oral Procainamide in Elderly Male Patients (ab) 450; (coauthor) see **Beach, C.L.**, 450, see **Bussey, Henry, I.**, 436, see **Green, Jeffrey A.**, 450

Fay, John T., Jr., VIP (WNC) 485

FDA News (WNC), acetaminophen's adverse effects, 862; AFP blood test kits "approvable" by FDA, 774; antibiotic certification, 78; ban on inhalant aphrodisiacs, 154; Bendectin labeling, 78; benoxaprofen, use authorized under compassionate IND, 318; Cambridge diet update, 398; camphorated oil, 78; charitable overseas distribution, unsafe foods, drugs, devices, 318; chondrolol approved, 774; chymopapain approved, 317; color additives update, 318; consumer legend drug advertising-current status, 862; contraceptive sponge approved, 485; cyclosporine, tentative approval, 862; drug manufacturers wanted for orphan drug monooctanoin, 318; epinephrine recall, 318; FDC Blue No. 2 to be listed, 154; fiscal 1984 budget request, 397; funds for orphan drugs made available, 154; generic drug controversy, U.S. Supreme Court rules, 485; glucomannan diet, 78; grants being awarded to support orphan drug products research, 688; human insulin approved, 77; konjac diet, 79; L-SHTP for myoclonus made available, 774; marijuana test kits—"positives" should be confirmed by an alternative method, 689; menstrual products reviewed, 398; metoprolol changed to OTC status, 154; moratorium issued on direct-to-consumer advertising, 940; national center for devices and radiological health, 153; new warning label statement for OTCs, 239; oral drug information more likely from doctors, 154; orphan drug approved, 774; orphan drug sodium cellulose phosphate approved, 397; orphan products development grants—a correction, 940; OTC sales of

potassium iodide, 318; pentazocine: new formulation approved, 318; pre-1962 ANDA acceptance clarified, 397; proposes to ease drug-testing requirements, 397; reclassification of contact lenses, 239; regulating recombinant DNA products, 317; review of OTC scalp products, 318; Revital seized, 78; Rey's syndrome and aspirin—latest status, 238; social security check stuffers, 485; starch blockers, 78; status of various artificial sweeteners, 606; sugar safe at current consumption levels, 239; sulfating agents, 397, 485; treatment of premenstrual syndrome, 774; two drugs switched to OTC status, 940; unlabeled indications, 77; use of approved drugs for unlabeled indications, 317

FDA see also Food and Drug Administration

Fedak, Stuart M. (author) Correction in CPR Team Article (L) 849

Fellowships and residencies, 1983-84 survey (A) 835

Fellowships and Residencies, California, University of Southern California, 226, 854; **Colorado,** Denver Veterans' Administration Medical Center, 385; **Connecticut,** Hartford Hospital, 929; **Florida,** University of Florida, 226, 227; **Georgia,** Emory University, 65, 142, 854, 928, Mercer University, 331, 766; **Indiana,** University Hospitals, 142; **Iowa,** University Hospitals and Clinics, 385; **Massachusetts,** Brigham and Women's Hospital, 929; **Minnesota,** St. Paul-Ramsey Medical Center, 142; **Missouri,** Greater Kansas City Mental Health Foundation, 65, University of Missouri-Kansas City, 65, 928, 930, Western Missouri Mental Health Center, 65; **Nebraska,** University Medical Center, 226; **New Jersey,** Rutgers University, 929; **New York,** The State University at Buffalo, 66, 931, University of Rochester Medical Center, 386; **Ohio,** Ohio State University, 766; **Pennsylvania,** Hamot Medical Center, 854, 928, University of Pittsburgh, 142; **Rhode Island,** Rhode Island Hospital, 766; **Texas,** The University M.D. Anderson Hospital, 226, 766, University of Texas, 929; **Virginia,** Medical College Hospitals, 66, 930

Ferguson, Joyce A. (author) book review, 388

Ferguson, R.K. (author) Strategies and Outcomes of a Warfarin Utilization Study: A Pronounced Heparin/Prothrombin Time Interaction (ab) 453; (coauthor) see **May, C.A.**, 433

Ferrous fumarate, obstetrics/gynecology (CTF) 674

Fleiss, Ellen (author) book review, 69, 478

Fink III, Joseph L. (author) Legal Issues Surrounding the Number of Dosage Units Dispensed (F) 756; (author) Liability Claims Based on Drug Use (A) 667

Finn, Andrew L. (coauthor) see **Comstock, T.J.**, 453

Fischels, Robert P., editorial comment on (E) 45

Fischer, James H. (coauthor) see **Curtis, Robert A.**, 443, see **Giacina, Nicola,** 452, see **Goff, D.**, 441, see **Searcy, C.J.**, 452, see **Zell, Michele,** 442

Fischer, John M. (author) Enhancement of Tricyclic Antidepressants by Thyroid (DIAS) 718

Fischer, L.J. (coauthor) see **Leff, Richard D.**, 448

Fisher, Diane J. (author) The Gap Between Basic Sciences and Clinical Pharmacy Practice: Is It Epistemological? (O) 210

Fleiss, Ellen, cardiovascular disease (CTF) 673

Fletcher, C.V. (author) Altered Gentamicin Distribution After Coronary Artery Bypass Surgery (ab) 447

Flunitrazepam, anesthesiology (CTF) 62

Flunitrazepam butyl, efficacy and safety, adults with perennial rhinitis (ab) 442

Fluorescein, diagnosis of cerebrospinal fluid rhinorrhea (DIAS) 186

Fluoroprednisolone-9, hypokalemia (A) 177

Fluorouracil, dermatology (CTF) 223

Fluphenazine, pharmacokinetics, high performance thin layer chromatography (ab) 436

Food and Drug Administration see also **FDA News;** policies, clinical pharmacists as investigators (ACCP) 676

Food and Drug Law Institute, teaching grants (WNC) 775

Forcione, Mario (author) Comment On Nadolol-Induced Tinnitus (L) 208

Foreign Abstracts, 71, 146, 231, 307, 390, 479, 597, 680, 769, 856, 934

Foreign Pharmacy Graduates, examination committee, meeting (WNC) 152

Forensic Pharmacy, Legal Issues Surrounding the Number of Dosage Units Dispensed (F) 756; Liability Claims Based on Drug Use (A) 667

Formaldehyde, toxicology (CTF) 475

Forney, Paul D. (coauthor) see **Davidson, Karen H.**, 229

Forney, R. (coauthor) see **Schwartz, J.**, 438

Foster, J. (coauthor) see **Powell, J. Robert,** 445

Fraile, Manuel (coauthor) see **Morell, Ferran,** 133

Franchise, Donald E., editorial comment on (E) 45

Frank, John J. (author) Acute Toxicity of Nonsteroidal Antiinflammatory Agents: Seizure Following a Mefenamic Acid Overdose (CR) 204

Fraser, Don (coauthor) see **Scavone, Joe,** 186

Frati, Maria Elisa (coauthor) see **Mas, Xavier,** 378

Freeman, C.M. (coauthor) see **Quandt, Christine M.**, 438

Freimer, Nelson (coauthor) see **Nabata, Milap C.**, 201

French Abstracts see **Foreign Abstracts**

Freytes, Cesar O. (coauthor) see **Holt, Robert J.**, 281

Fricker, F.J. (coauthor) see **Burckart, Gilbert J.**, 446

Friedman, Basil A. (coauthor) see **Masterson, Barry J.**, 51

Frogameni, A. (coauthor) see **Schwartz, J.**, 438

Frost, G.L. (coauthor) see **Mueller, C.E.**, 440

Frui, Dennis (coauthor) see **Stein, Z.L.G.**, 561

Fujita, Toshio (coauthor) see **Koshino, Akira,** 351

Furniss, Leesa D. (author) Corrections to Drug Information Letter (L) 913; (author) Rash Due to Erythromycin (DIAS) 631

Furosemide, compared with bumetanide (NDE) 786; hypocalcemia (A) 180; interactions, gentamicin (DIR) 107

Furste, Ann L. (coauthor) see **Lewis, Thomas W.**, 469

Furukawa, Fumitaka (coauthor) see **Ohnawa, Tomoji,** 739

G

- Gabrielson, R.M.** (author) Colistin and Otolotoxicity (L) 48
Gaginella, Timothy S. (author) Diarrhea: Some New Aspects of Pharmacotherapy (E) 914; author
 Ranitidine Hydrochloride (NDE) 873
Gagnon, Jean Paul (author) see **Carroll, Norman V.**, 648
Gal, Peter (author) Asphyxia Lowers Phenobarbital Dosing Requirements in Newborns (ab) 434; (coauthor) see **Oles, Karen S.**, 438
Gallinsky, Raymond E. (author) Clinical Scientist or Pharmacy Administrator? (L) 377; (author) Reimbursement for Clinical Pharmacy Services (L) 293
Galvan, Eustacio (coauthor) see **Guernsey, Brock G.**, 742
Ganju, Shihban K. (coauthor) see **Mendel, Stephen A.**, 640
Garcia, Sonia V. (coauthor) see **Julia, Angiolina M.**, 580
Gardner, Jr., Russell (coauthor) see **Seifert, Randall**, 470
Garrard, C. (coauthor) see **Curtis, Robert A.**, 443
Garrelis, J.C. (coauthor) see **Farringer, J.A.**, 450
Garriott, J. (coauthor) see **Watson, W.A.**, 441
Garzone, Pamela (author) Third-Generation and Investigational Cephalosporins: I. Structure-Activity Relationships and Pharmacokinetic Review (A), 507; (author) Third-Generation and Investigational Cephalosporins: II. Microbiological Review and Clinical Summaries (A) 615
Gastroenterology (CTF), bethanechol, 63; cimetidine, 760; corticotropin, 924; domperidone, 303; glucagon, 63; metronidazole, 63; naloxone, 474; nitroglycerin, 383; ranitidine, 383, 850; spironolactone, 673; ursodeoxycholic acid, 63; vasopressin, 223
Gastroenterology panel, ranitidine evaluation (NDE) 873
Gaynor, Hollie (coauthor) see **Jochsberger, Theodore**, 550, 849
Gelbart, A.O. (coauthor) see **Patris, J.M.**, 454
Gemfibrozil, cardiovascular disease (CTF) 850
General Medicine (CTF), court rules, (WNC) 485
Genitacimil, altered distribution, coronary bypass (ab) 447; dosing guidelines evaluation (A) 425; effect on urinary enzyme excretion (L) 752; geriatrics (CTF) 303; hypokalemia (A) 177; interactions, furosemide (DIR) 107; in vitro inactivation by carbenicillin, compared by EMIT and microbiological assays (ab) 451; pharmacokinetic parameters, dosage recommendations, with radioimmunoassay and fluorescent polarization immunoassay, 444; pharmacokinetics on a microcomputer (A) 35; urology (CTF) 674
Geriatrics, comparison of lean body weight formulas for determining digoxin dose (ab) 454; drug abuse, (E) 657; patient information, consultation, cognitive variants (G) 840; pharmacy practice, pharmacists' perceptions (G) 134; Receipt of Prescription Drug Information by the Elderly, 920; use of anticholinergics, nursing home (G) 470
Geriatrics (CTF), gentamicin, 303; gold sodium thiomalate, 850; physostigmine, 673; urinary incontinence, 303
Geriatrics and Gerontology, Cognitive Variants in the Elderly: An Integral Part of Medication Counseling, 840; Drug Use and Accidental Falls in an Intermediate Care Facility, 539; Effect of Chlorophyllin on Urinary Output in Incontinent Geriatric Patients, 732; Evaluation of Hypertensive Therapy in a Skilled Nursing Facility, 39; Pharmacists' Perception of Geriatric Pharmacy Practice, 134; Receipt of Prescription Drug Information by the Elderly, 920; Use of Anticholinergics in the Nursing Home: An Empirical Study and Review, 470
Geriatrics panel, triazolam evaluation (NDE) 495
Giacosa, Nicola (author) Diurnal Variation in Theophylline Elimination (ab) 452
Giardia, prevention in drinking water (DIAS) 344
Giardiasis, drug regimen in pregnancy (DIAS) 187
Gilliam, R.V. (coauthor) see **Senholzi, Craig S.**, 445
Glazer, J.P. (coauthor) see **Nahata, Milap C.**, 439
Glazer, Norman (coauthor) see **Materson, Barry J.**, 51
Glucagon, gastroenterology (CTF) 63
Glucocorticoids, promoted as diet aid (WNC) 79
Glucose/insulin, interactions, cimetidine (A) 114
Goff, D. (author) Evaluation of Oral Loading Doses of Phenytoin (ab) 441
Gold, lack of correlation, between blood levels and clinical response, rheumatoid arthritis (ab) 449
Gold sodium thiomalate, geriatrics (CTF) 850
Goldberg, M.J. (coauthor) see **Park, Glen D.**, 435
Goldstein, Murray, VIP (WNC) 607
Gotz, Vincent P. (author) Influence of Medroxyprogesterone on Theophylline Disposition (ab) 434; (coauthor) see **Brandstetter, Robert D.**, 125
Gourley, Dick R. (coauthor) see **Kimberlin, Carole L.**, 297
Goyan, Jere E. (author) Science: Part of the Problem, Most of the Answer (A) 566
Gracia, J. de (coauthor) see **Morell, Ferran**, 820
Graham, E. Michael (coauthor) see **Jeffers, William H.**, 372
Gram-negative infections, treatment (NDE) 83
Grasela, Dennis M. (author) Multiple-Dose Cimetidine Does Not Affect Indocyanine Green Clearance (ab) 454
Graves, Terri (author) Treatment of L-Asparaginase Allergic Reaction (CR) 130
Gray, James M. (coauthor) see **Materson, Barry J.**, 51
Greco, Richard E., VIP (WNC), 941
Green tobacco sickness, dimenhydrinate (CR) 548

- Green, A.A.** (coauthor) see **Crom, William R.**, 448
Green, Jeffrey A. (author) Clinical Evaluations of Newly Marketed Preparations as a Basis for Drug-Product Selection to Hospital Pharmacy Formulary (ab) 450; (author) Decrease in Theophylline Clearance After the Administration of Erythromycin to a Patient with Obstructive Lung Disease (CR) 370
Greenwood, John (author) Communication Between Pharmacist and Patient (L) 468
Greico, Mario L. (coauthor) see **Quattrocchi, Frank P.**, 286
Griffin, Gerald D. (author) The Use of Protein Therapy for Drug Overdose (L) 202
Griffith, B. (coauthor) see **Burckart, Gilbert J.**, 446
Gross, Steven (coauthor) see **Materson, Barry J.**, 51
Gruclala, Maria (coauthor) see **Wichlinski, Leslaw M.**, 812
Guay, David R.P. (author) Neimilicin (NDE) 83; (coauthor) see **Meatherall, Robert C.**, 755
Guernsey, Brock G. (author) Personal Nitroglycerin Containers (L) 734; (author) Pharmacists' Dispensing Accuracy in a High-Volume Outpatient Pharmacy Service: Focus on Risk Management (RPR) 742
Guerrero, Juan R. (coauthor) see **Martin, Susan S.**, 206
Guglielmo, B. Joseph (coauthor) see **Quart, Barry D.**, 462
Guharoy, Sudip (coauthor) see **Jimenez, Mark D.**, 644
Guild, R.T. (coauthor) see **Russell, W.L.**, 439
Guthrie, Troy V. (coauthor) see **Graves, Terri**, 130
Gynecology see **Obstetrics/Gynecology**
H
Hadsall, Ronald S. (coauthor) see **Kimberlin, Carole L.**, 297
Haffajee, Charles I. (coauthor) see **Canada, Andrew T.**, 100
Hahn, Deborah A. (author) Hexamethylmelamine and Pentamethylmelamine: An Update (A) 418
Hak, Larry J. (author) Acceleration of Peritoneal Dialysis Clearance with Docusate Sodium (ab) 440
Haloperidol, adverse reactions, cholestatic liver disease (CTF) 64; anesthesiology (CTF) 302; clinical response, acute psychosis (ab) 445; overdose-induced torsade de pointes (ab) 440; psychiatry (CTF) 64
Halperin, Jerome A. (author) Necessary, Optional, and Undesirable Drug Products (A) 574; VIP (WNC) 689
Hallstrom, Charles E. (author) Bumetanide: A New Loop Diuretic (NDE) 786
Hamilton, Robert A. (coauthor) see **Carter, Barry L.**, 23
Hansa, Jr., William R. (coauthor) see **Cady, William J.**, 645
Hann, Philip (author) Comments and Corrections on Dosing Guidelines (L) 911
Hanson, Capt. Kenneth E., VIP (WNC) 607
Hansen, Philip D. (author) book review, 765
Hardesty, R. (coauthor) see **Burckart, Gilbert J.**, 446
Harker, C.A. (author) see **Hughes, G.**, 436
Harless, Glenn R. (author) Note on Interactions Involving Theophylline Kinetics (L) 132
Harralson, Arthur F. (coauthor) see **Tindula, Robert J.**, 906
Harris, S.C. (coauthor) see **Beach, C.L.**, 450, see **Farringer, J.A.**, 450
Hart, Linda L. (coauthor) see **Cheu, Gilbert S.**, 345, see **Noud, Mary**, 720; (editor) DIAS Rounds, 186, 264, 342, 629, 718, 808
Hartshorn, Edward A. (author) Comment on Valproic Acid Interactions (L) 294
Hattersley, Paul G. (author) Adjusting Heparin Infusion Rates From the Initial Response to Activated Coagulation Time (A) 632
Hayes, F.A. (coauthor) see **Crom, William R.**, 448, see **Hutson, Paul R.**, 442
Hays, Dennis P. (author) Bendectin: A Case of Mourning Sickness (E) 826
Health and Human Services see **HHS News**
Heart, electrical conduction (PA) 250; physical assessment of (PA) 248
Hedrick, P.J. (author) Electrophysiologic Variables Correlated with Propranolol Blood Levels in the Chronically Instrumented Puppy (ab), 443
Hegyi, T. (coauthor) see **Stile, L.L.**, 440
Hekster, Yechiel A. (coauthor) see **Elenbaas, Robert M.**, 722, see **Vree, Tom B.**, 131, 267
Heller, Andrew S. (coauthor) see **Carson, Herbert B.**, 277
Heller, William M. (author) Dispensing in 1982, Rho Chi Lecture Award (A) 570
Hematology (CTF), epoprostenol (prostacyclin) 383; immunoglobulin, 591; lithium, 673; prednisone, 63; vincristine, 591; warfarin, 383
Hemodialysis, nitrogen intake, urea appearance (ab) 434
Hendles, Les S. (coauthor) see **Hill, Malcolm R.**, 452
Henderson, Robert P. (author) Spiking Fever Induced by Isoniazid (CR) 741
Heparin, adjusting infusion rates (A) 632; cardiovascular disease (CTF) 850; hypocalcemia (A) 179; kinetics during hemodialysis (ab) 451; nutrition (CTF) 474, 760
Hepatic dysfunction, carbamazepine-induced (CR) 642
Hepatitis B, immune globulin, pediatric (CTF) 592; vaccine, acquired immune deficiency syndrome, discussion (A) 800; virus vaccine, safety of (WNC) 399
Herbst, J.J. (coauthor) see **Bosso, John A.**, 435
Herpes simplex, update on treatment (WNC) 774; virus, use of lysine (DIAS) 186
Hershey, L.A. (coauthor) see **Miller, Del D.**, 445
Hetastarch, chemistry (A) 334; clinical efficacy (A) 335; disposition (A) 337; general medicine (CTF) 924; overview of the colloid and its metabolism (A) 334; side effects (A) 337; use, septic shock (CC) 96
Hexamethylmelamine, update (A) 418
HHS News (WNC), children as subjects, scientific research, 484; common coding system announced by HHS and AMA, 398; hospitals must post notice concerning the legal rights of handicapped infants,

- 485; infant mortality rate declines in U.S., 484; J. Solon Mordell tribute, 319; new FDA guidelines, plasma centers and blood banks, 484; orphan drug bill now public law, 237; OTC packaging, 79; research funds increases for Alzheimer's disease, 484; tamper-resistant packaging, 79
Hiatt, L.M. (coauthor) see **Stile, L.L.**, 440
Higuchi, Takeru, VIP (WNC) 611
Hill, Malcolm R. (author) Changing Chloramphenicol Serum Concentrations During Therapy (ab) 452
Hilty, Milo D. (coauthor) see **Nahata, Milap C.**, 201
Hla, Khin Mae (coauthor) see **Materson, Barry J.**, 51
Hodgman, Tudy (coauthor) see **Armstrong, D.**, 437
Hoelzer, D.R. (coauthor) see **DeLaFuenta, Jeffrey C.**, 433
Hoff, J.V. (author) Efficacy and Safety of Oral Atenolol in Paroxysmal Supraventricular Tachycardia (ab) 440
Hoffer, L. (coauthor) see **Reitz, Jeffrey A.**, 437
Hogan, Linda (coauthor) see **Wilson, Judy**, 54
Hokanson, James A. (coauthor) see **Guernsey, Brock G.**, 742, 754
Holt, Robert J. (author) Familial Warfarin Resistance (CR) 281; (author) Neuroleptic Drug-Induced Thrombocytopenia (ab) 437
Hopell, Alan W. (author) The Clinical Use of Intravenous Acyclovir (NDE) 623
Hopkins, L.E. (coauthor) see **Ferguson, R.K.**, 453
Horn, John R. (author) book review, 228
Horst, H.M. (coauthor) see **Quandt, Christine M.**, 438
Howick, J. (author) Absorption Characteristics of a New Sustained-Release Theophylline Sprinkle for Infants and Young Children (ab) 445
Howie, M.B. (coauthor) see **Reitz, Jeffrey A.**, 437
Howrie, Denise L. (coauthor) see **Schwinghammer, Terry L.**, 460
Huber, Stephen L. (author) book review, 144
Hübner, Jay W. (coauthor) see **Frank, John J.**, 204
Huckendubler, S. (coauthor) see **Bosso, John A.**, 435
Hughes, G. (author) Therapeutic Naloxone for Septic Shock (ab) 436
Hulse, James D. (author) book review, 927; (author) Hetastarch: An Overview of the Colloid and its Metabolism (A) 334
Hume, Anne Lamont (author) Ketoconazole (NDE) 169
Hunt, Stephanie A. (author) Subminimally Inhibitory Concentrations of Antimicrobials (L) 560
Husain, F. (coauthor) see **Watson, W.A.**, 441
Hutchinson, Richard A. (author) book review, 927
Hutson, Paul R. (author) Pharmacokinetics of Etoposide in Children with Refractory Solid Tumors (ab) 442
Hydrochloric acid, general medicine (CTF) 303, 760
Hydrochlorothiazide, adverse reactions, acute pulmonary edema, leukopenia and thrombocytopenia (CTF) 384; cardiovascular disease (CTF) 140; hypercalcemia (A) 180; hyponatremia (A) 176; pediatrics (CTF) 303; rheumatology (CTF) 925
5-Hydroxytryptophan, psychiatry (CTF) 592; (WNC) 774
Hyperbilirubinemia, aminoglycoside concentrations, falsely elevated by (CR) 544
Hypercalcemia, drug-induced (A) 180; treatment with mithramycin, phosphates, calcitonin, chelating agents, dialysis, and steroids (A) 12
Hyperkalemia, drug-induced (A) 178
Hypernatremia, drug-induced (A) 176
Hypersensitivity, influence of age and disease state, delayed cutaneous hypersensitivity (ab) 433
Hypertension, evaluation, skilled nursing facility (G) 39; labetalol, use in (NDE), 40; slow-release oxprenolol compared with oxprenolol, multicenter clinical trial (RPR) 51
Hypertriglyceridemia, problem with parenteral nutrition (CR) 458
Hypocalcemia, drug-induced (A) 179
Hypophyemia, with disopyramide phosphate (A) 635
Hypokalemia, drug-induced (A) 177
Hypomagnesemia, drug-induced (A) 180
Hyponatremia, drug-induced (A) 175
Hypoprotrombinemia, naproxen overdose (CR) 549
I
Ibanez, Luisa (coauthor) see **Mas, Xavier**, 378
Ibuprofen, serum digoxin concentrations (RPR) 286; interactions, phenytoin (CTF) 304
Ibuprofen/naproxen, adverse reactions, cognitive dysfunction (CTF) 141
Ignoffo, Robert J. (coauthor) see **Hattersley, Paul G.**, 632
Imipramine, bulimia nervosa treatment (LA) 815; psychiatry (CTF) 303
Immunobiological agents, general medicine (CTF) 223
Immunoglobulin, hematology (CTF) 591
Imoto, Ronald (author) Metoprololamide in patients with renal failure (DIAS) 264
Indapamide, discussion (LA) 898
Indocyanine green, effect of multiple-dose cimetidine on clearance (ab) 454; pharmacokinetics, comparison of analytical methods (ab) 446
Indomethacin, ophthalmology (CTF) 761; pediatrics (CTF) 851; renal disease (CTF) 304
Industry, pharmaceutical, drug information, survey (A) 27; training and liaison for personnel (WNC) 237
Industry News (WNC), Tylenol Extra-Strength returns to marketplace, 238
Infant mortality, rate declines in U.S. (WNC) 484
Infants, rights of handicapped in hospitals (WNC) 485
Infection, abdominal, antibiotic penetration of moxalactam (CR) 277; fungal, complications, acquired immune deficiency syndrome (A) 802; herpes, use of acyclovir (DIAS) 809; opportunistic, associated with acquired immune deficiency syndrome (A) 798, management of (A) 798; viral, complications, acquired immune deficiency syndrome (A) 802
Infectious Disease (CTF), acyclovir, 63, 383, 673, 760, 850; amikacin, 63, 303; carbenicillin, 474;

cefoperazone, 591, 760; cefotaxime, 140, 223; ceftriaxone, 924; clindamycin, 303, 673; cotrimoxazole, 850; dioxuridine, 63; isoniazid, 383; ketoconazole, 383, 474, 924; metronidazole, 140; mezlocillin, 383; minocycline, 924; moxalactam, 223, 924; penicillin G, 223; piperacillin, 303; ribavirin, 673; rifampin, 303; rimantadine, 63; tinidazole, 63; trimethoprim, 383; trimethoprim and co-trimoxazole, 140; vancomycin, 63, 223; vidarabine, 140.

Infectious disease panel, IV acyclovir evaluation (NDE) 623

Influenza, surveillance summary, 1982-83 season (WNC) 775; vaccines, recommended composition for 1983-84 season (WNC) 689

Ingrin, Naomi B. (coauthor) see Guernsey, Brock, G., 742, 754

Injections, intravenous, infusions, overall effects (L) 847

Institutional review board, policies in research (A) 831; protocol guidelines (A) 833; requirements for informed consent (A) 828; role in research (A) 828

Insulin, adverse reactions, allergy to purified pork (CR) 818; biosynthetic human insulin approved by FDA (WNC) 77; continuous subcutaneous infusion pumps (WNC) 153; endocrinology (CTF) 591; hypokalemia (A) 178; interactions, plastics (DIR) 726; pork, highly purified, allergy to (CR) 818

Interactions see Drug Interactions

Interferon, immunoreactive agent in acquired immune deficiency syndrome (A) 801; neurology (CTF) 223

Intermediate care facility, drug use and accidental falls (G) 539

International Reports, Drug Prescribing and Use Among Elderly People in Spain, 378; Hospital Pharmacy in Portugal and Its Future Trends, 843

Intravenous Therapy (CTF), cephalosporins, 383; lorazepam, 591; moxalactam, 140

Investigational Drug Information, pirofen, 894

Isoctamic acid, adverse reactions, thrombocytopenia (CTF) 851

Iron preparations, interactions, occult blood tests (CTF) 141

Isaacs, Michael L. (coauthor) see Baciwicz, Anne M., 57

Isonitrite, linked with AIDS (WNC) 154

Isoniazid, infectious disease (CTF) 383; interactions, carbamazepine (CTF) 224; spiking fever (CR) 741

Isoquinoline, immunoreactive agent in acquired immune deficiency syndrome (A) 801

Isopterenol, pulmonary disease (CTF) 384; use in septic shock (CC) 97

Isoorbide, interactions, plastics (DIR) 729; dinitrate, adverse reactions, hemolytic anemia (CTF) 475

Isoretinoin, adverse reactions, skeletal hyperostosis (CTF) 674; availability and cost (NDE) 333; clinical use (NDE) 331; contraindications (NDE) 332; dosage and administration (NDE) 333; oral therapy for disorders of keratinization (ab) 437; pharmacokinetics (NDE) 330; pharmacology (NDE) 329; recalcitrant cystic acne (NDE) 329; side effects and adverse reactions (NDE) 331

Iverson, P. (coauthor) see Seifert, Randall, 451

Ives, Timothy J. (author) Use of dimenhydrinate in the Treatment of Green Tobacco Sickness (CR) 548

J

Jackowitz, Ari (author) Addendum to Drug Information Listing (L) 654

Jackson, Eric A. (editor) New Drug Evaluations: Cefoperazone, 7

Jaimes, Laura (coauthor) see Jimenez-Alonso, Juan, 752

Jamali, Fakhraddin (author) Naproxen Excretion in Milk and its Uptake by the Infant (L) 910

Jamieson, John (coauthor) see Seifert, Randall, 470

Janacek, Douglas A. (author) Allergic Reaction to Purified Pork Insulin (CR) 818

Jann, M.W. (coauthor) see Ereshefsky, Larry, 436

Jauregui, L. (coauthor) see Schwartz, J., 438

Jeffery, William H. (author) Treatment of Chlorpropamide Overdose With Diazepam (CR) 372

Jenick, John A. (author) book review, 69

Jimenez-Alonso, Juan (author) Effect of Amikacin and Gentamicin on Urinary Enzyme Excretion (L) 752

Jimenez-Pererez, Jose A. (coauthor) see Jimenez-Alonso, Juan, 752

Jimenez, Mark D. (author) Tricyclic-Induced Seizure Activity (CR) 644

Jinks, Martin J. (author) Author's Reply (L) 48; (author) book review, 68

Joad, J. (coauthor) see Smith, Gary D., 442

Jochsberger, Theodore (author) Authors' Reply: Comment on Brand of Aspirin and Serum Levels (L) 849; (author) Comment on Determining Loading Dose for a Multiple Dosing Regimen (L) 376; (author) Effect of Brand on the Serum Level of Aspirin (CR) 550

Johnson, Brian (coauthor) see Canada, Andrew T., 100

Johnson, G.F. (coauthor) see Park, Glen D., 435

Johnson, Kenneth B., VIP (WNC) 689

Johnson, Philip N. (author) book review, 307

Jolly, M.King (coauthor) see Farringer, J.A., 450

Jones, Mark (author) book review, 306

Juhl, Randy P. (coauthor) see Kroboth, Patricia Dowley, 447, 495

Julia, Angiolina M. (author) Spanish Labeling Guide (A) 580

Julian, Kathryn A. (author) Comment on Nitroglycerin Article (L) 754

Junck, Jeffrey W. (author) Is It a Matter of Degree? (L) 561

Jung, D. (coauthor) see Goff, D., 441

Jusko, William J. (coauthor) see Christoff, Patricia B., 516

K

Kaka, Juzar S. (author) Aminoglycoside Pharmacokinetics on a Microcomputer (A) 33

Kalu, Mma (coauthor) see Moore, Steven R., 920

Kamp, Judith (coauthor) see Nahata, Milap C., 732

Kanamycin, pharmacokinetics on a microcomputer (A) 35

Kaposi's sarcoma, acquired immune deficiency syndrome, discussion, 798

Kapusnik, Joan E. (coauthor) see Barriere, Steven L., 265; see Giacomini, Nicola, 452

Katkov, H. (coauthor) see Schaber, D.E., 439

Kaul, Alan F. (author) Author's Reply: Comment on DEHP Toxicity (L) 293; (author) Postgraduate Pharmacy Fellowships (1983-1984) (A) 835; (coauthor) see Vogenberg, F. Randy, 912

Kavanaugh, J. (coauthor) see Searcy, C.J., 452

Kawasaki, Gail (coauthor) see Zeisler, John A., 207

Keatinge, Daniel W. (coauthor) see Waugh, Phyllis K., 549

Kellher, Mark P. (author) Lack of Support for Clinical Pharmacy: A PHS Cuban Refugee Experience (L) 207

Kelly, H. William (coauthor) see Howick, J., 445

Kelly, Kim (author) Author's Reply: Comment on Programmable Calculators (L) 49

Kennedy, M.S. (coauthor) see Yee, Gary C., 451

Kerker, Thomas M. (coauthor) see Hume, Anne Lamont, 169

Ketoconazole, adverse reactions, decreased testosterone concentrations (CTF) 384; availability and cost (NDE) 173; clinical trials (NDE) 171; dermatology (CTF) 63, 140, 383, 673; dosage and administration (NDE) 173; drug interactions (NDE) 173; in fungal infections, associated with acquired immune deficiency syndrome (A) 803; infectious disease (CTF) 383, 474, 924; interactions, cimetidine (A) 115; microbiology (NDE) 170; new drug evaluation (NDE) 169; obstetrics/gynecology (CTF) 925; pharmacokinetics (NDE) 170; pharmacology (NDE) 169; side effects and adverse reactions (NDE) 172; toxicity (NDE) 172

Kittie, H. (coauthor) see Bishop, M.P., 132

Kimberlin, Carole L. (author) Predicting Success of Pharmacy Students in Basic Science and Clinical Clerkship Courses (A) 297

Kinetics, see Pharmacokinetics

King, Jeffrey H. (coauthor) see Hattersley, Paul G., 632

Kirking, Duane M. (author) book review, 852

Kirschenbaum, Harold (coauthor) see Jochsberger, Theodore, 550, 849

Kishi, D.T. (coauthor) see Conte, R.R., 442

Klinger, J. (coauthor) see Reed, Michael D., 446

Knutson, R. (coauthor) see Seifert, Randall, 451

Koch, Todd B. (coauthor) see Carson, Herbert B., 277

Kohli, R. (coauthor) see Slaughter, Richard L., 440

Kohl, Kenneth W. (author) Comment on Aminoglycoside Program (L) 375

Kook, K.A. (author) Accuracy and Safety of A Priori Lithium Loading and Maintenance Dosing (ab) 453

Koshiro, Akira (author) Interaction of Penicillins with the Components of Plasma Expanders (A) 351

Kotter, S. (coauthor) see Hak, Larry J., 440

Kotzian, Jeffrey A. (coauthor) see Wiederholt, Joseph B., 216

Kowalczyk, A. (coauthor) see Hedrick, P.J., 443

Kramer, Paul A. (author) book review, 595, 853

Kraus, A.P. (coauthor) see Comstock, T.J., 453

Kroboth, Patricia Dowley (author) Pharmacokinetics and Psychomotor Effects of Triazolam in Dialysis Patients and the Effect of Aluminum Hydroxide on Triazolam Absorption (ab) 447; (author) Triazolam (NDE) 495

Kryc, J. (coauthor) see Reitz, Jeffrey A., 437

Kudsk, Kenneth A. (author) Nutritional Support of the Critically Ill Patient (C) 501

Kumer, Kenneth P. (author) Perspectives on Digoxin Absorption from Small Bowel Resections (RPR) 121

Kuo, Chien Suu (coauthor) see Bortoff, Michael B., 279

L

L-Asparaginase, adverse reactions, allergic reaction (CR) 130, hyperthermia (CTF) 116

L-5 hydroxytryptamine, made available for myoclonus (WNC) 774; psychiatry (CTF) 592

L-Tryptophan, general medicine (CTF) 924

Labels, auxiliary, readability testing (RPR) 54

Labetalol, adverse reactions (NDE) 708; an alpha- and beta-blocker (LA) 543; clinical trials (NDE) 706; dosage (NDE) 709; drug interactions (NDE) 709; pharmacokinetics (NDE) 705; pharmacology (NDE) 704

Lackner, Thomas E. (author) Author's Reply: Comment on Monitoring Aminoglycoside Serum Levels (L) 50

Lactulose, water loss (A) 177

Lamy, Peter P. (author) Drug Abuse by Older Adults: Who is Responsible? (E) 657; (editor) Geriatrics and Gerontology, 39, 134, 470, 539, 732, 840, 920

Lanc, Robert A. (coauthor) see Slaughter, Richard L., 274

Lander, Roger (author) Adverse Reactions with Diazepam (DIAS) 630

Landes, Robert A. (coauthor) see Taketomo, Robert T., 821

Lapierre, Ginette (author) Evaluation of Hypertensive Therapy in a Skilled Nursing Facility (G) 39

Laporte, Jean-Ramon (coauthor) see Mas, Xavier, 378; (coauthor) see Morell, Ferran, 133, 820

Lau, Alan (author) The Pharmacokinetics of Metronidazole in Patients with Alcoholic Liver Disease (ab) 436

Laws, litigation, Bendectin, comment on (E) 826; (L) 848; witness, expert, comment on (L) 848

Lead, toxicology (CTF) 925

Leal, Aluisio Marques (author) Hospital Pharmacy in Portugal and Its Future Trends (IR) 843

LeBel, Marc (author) Lack of Interference of Five New Beta-Lactam Antibiotics with Serum Creatinine Determination (RPR) 908

Leclishin, psychiatry (CTF) 140

Lee, Mary (author) Equivalence of Levthyroxine Tablets (DIAS) 265; (author) Steroids and Avascular Bone Necrosis (DIAS) 343; (coauthor) see Chan, Marianne, 809

Leff, Richard D. (author) Phenytoin Disposition After Intravenous and Oral Administration in the Neonate (ab) 448

LeFrock, Jack L. (coauthor) see Smith, B.R., 433

LeGat, Donald F. (author) Theophylline Toxicity—A Consequence of Congestive Heart Failure (CR) 59

Legislation, pharmacy, Veterans' Administration, central office appointments (E) 864

Leiberman, A. (coauthor) see Schaeffer, F., 899

Leiberman, Louis, VIP (WNC) 607

Lener, L. (coauthor) see Beach, C.L., 450

Lesko, Lawrence J. (coauthor) see Canada, Andrew T., 100

Letters, A Marginal Profession?, 50; Addendum to Drug Information Listing, 654; Alert Concerning Salt Tablets, 377; Assassin Bug Toxemia, 753; Authors' Replies: Clinical Scientist or Pharmacy Administrator?, 377, Colistin and Otitotoxicity, 48; Comment on a Case of Thiazide-Induced Hyponatremia, 205, Aminoglycoside Program, 375, Brand of Aspirin and Serum Levels, 849; Care of the Critically Ill, 558, DEHP Toxicity, 293, Drugs, Alcohol, and Sex Review, 293, Kinetic Predictions of Serum Drug Concentrations, 654, Monitoring Aminoglycoside Serum Levels, 50, Nitroglycerin Article, 754, Programmable Calculators, 48, Comments and Corrections on Dosing Guidelines, 911, Correction in CPR Team Article, 849; Creatinine Clearance and Urine Flow, 131, Is It a Matter of Degree?, 561, Neurotoxicity with Amoxapine Overdose: A More Reasonable Perspective, 132; Choline Theophyllinate Every Eight Hours, 133; Clinical Scientist or Pharmacy Administrator?, 377; Colistin and Otitotoxicity, 48; Comment and Case Report on Dose-Dependent Theophylline Elimination, 847; Comments on: a Case of Thiazide-Induced Hyponatremia, 205, Aminoglycoside Program, 375, Antimicrobial Susceptibility Testing, 207, APHA Resolution, 469, Brand of Aspirin and Serum Levels, 849, Calculator Program for Adjusting Aminoglycoside Dosage, 377; Care of the Critically Ill, 558, Chlorpropamide Overdose, 755, DEHP Toxicity, 292, Determining Loading Dose for a Multiple Dosing Regimen, 376, Difficult Monitoring Situation, 469, Drugs, Alcohol, and Sex Review, 293, Intravenous Nitroglycerin, 49, 754, Kinetic Predictions of Serum Drug Concentrations, 653, Maprotiline Article, 558, Monitoring Aminoglycoside Serum Levels, 49, Nadolol-Induced Tinnitus, 208, Nitroglycerin Article, 754, Orphan Drugs, 912, P.D. Degree, 133, Programmable Calculators, 48, Theophylline Dosing, 469, Titles and Degrees, 755, Valproic Acid Interactions, 294, Verapamil Evaluation, 206, Comments and Corrections on Dosing Guidelines, 911; Commercial IV Fluid Overfill Effects on Continuous-Infusion Drug Administration and Assessment, 847; Communication Between Pharmacist and Patient, 468; Communications Skills: Catalyst for Clinical Practice in Pharmacy and Nursing, 467; Corrections: Aminoglycoside Program Article, 50, Auxiliary Labels, 294, CPR Team Article, 849, Drug Information Article, 655, Drug Information Letter, 913, Self-medication Abuse or Misuse, 469, Septic Shock Article, 284; Creatinine Clearance and Urine Flow, 131; Doctoring Titles, 562; Effect of Amikacin and Gentamicin on Urinary Enzyme Excretion, 752; Ephedrine-Phenobarbital Formulations, 653; Ethylene Glycol Toxicity and Treatment, 376; Expansion of an Investigational Drug Service, 912; Is It a Matter of Degree?, 561; Lack of Support for Clinical Pharmacy: A PHS Cuban Refugee Experience, 207; More Convenient Use of NONLIN, 467; Naproxen Excretion in Milk and its Uptake by the Infant, 910; Neurotoxicity with Amoxapine Overdose: A More Reasonable Perspective, 131; Note on Interactions Involving Theophylline Kinetics, 132; Personal Nitroglycerin Containers, 754; Programmable Solution for the Michaelis-Menten Equation, 559; Reimbursement for Clinical Pharmacy Services, 293; Subminimally Inhibitory Concentrations of Antimicrobials, 560; Title Irrelevant to Character, 654; Torsade de Pointes: A Rare Tachyarrhythmia, 561; Two Legal Issues: Expert Witnesses and Bendectin Case, 848; Use of Protein Therapy for Drug Overdose, 292

Levamisole, immunoreactive agent in acquired immune deficiency syndrome (A) 801

Levartanol, use in septic shock (CC) 97

Levodopa, interactions, chlorazepoxide (DIR) 106

Levothyroxine, tablet equivalence (DIAS) 265

Levy, Rene H. (coauthor) see Bauer, L.A., 434

Lewis, G.P. (coauthor) see LeBel, Marc, 908

Lewis, Thomas W. (author) Comment on Difficult Monitoring Situation (L) 469

Lidocaine, anesthesiology (CTF) 673; clinical assessment of a two-compartment Bayesian forecasting method (ab) 450; dose-dependent duration of lidocaine-induced seizures (ab) 441; interactions, cimetidine (A) 113, (DIR) 108, prenylamine (DIR) 106; lack of interaction with cimetidine in patients with suspected myocardial infarction (ab) 445

Linkewich, Joseph A. (coauthor) see Massaro, Frank J., 368

Lipscomb, Gary L. (coauthor) see Baciewicz, Anne M., 57

Lipscomb, Jack W. (coauthor) see Stein, Z.L.G., 376
Literature, 68, 144, 228, 306, 387, 478, 595, 679, 765, 852, 926; see Book Reviews, Books Received

Literature Analysis, Alzocillin, 222; Efficacy and Safety of Nicotine Gum, 52; Indapamide: A Unique Diuretic, 898; Intravenous Streptokinase in Acute Myocardial Infarction, 367; Labetalol: An Alpha- and Beta-Blocker, 543; Nifedipine: Two New Uses, 457; Prophylaxis of Neonatal Conjunctivitis, 139; Sleep Apnea, 736; Treatment of Syndrome Malin, 639; Treatment of Bulimia, 815; Ursodeoxycholic Acid: Superior to Chenodiol, 302

Lithium, accuracy and safety, loading and maintenance dosing (ab) 453; adverse reactions, lupus-like syndrome (CTF) 64; renal toxicity (CTF) 384, withdrawal effects (CTF) 925; bone marrow effects (A) 347; cardiac effects (A) 346; central nervous system effects (A) 346; dermatologic effects (A) 347; gastrointestinal effects (A) 347; hematology (CTF) 673; hypermagnesemia (A) 181; interactions, amiloride (DIAS) 809, aspirin (CTF) 592; metabolic and endocrine effects (A) 347; recommendations for monitoring therapy (A) 346; renal effects (A) 348

Lithium carbonate, associated with water loss (A) 177; pulmonary disease (CTF) 141

Loertscher, M. Vance (author) Author's Reply: Comment on Aminoglycoside Program (L) 375; (author) Correction to Aminoglycoside Program Article (L) 50

Lomas, Christopher (author) Author's Reply: Is It a Matter of Degree? (L) 561; (author) Comment on P.D. Degree (L) 133

Lomustine, adverse reactions, fatal pulmonary toxicity (CTF) 304

Longe, R. Leon (coauthor) see Patrias, J.M., 454; see Scamman, John J., 248; (editor) Physical Assessment

Lopez, L.M. (coauthor) see Russell, W.L., 439
Lorazepam, interactions, ethanol (CTF) 592; intravenous therapy (CTF) 591; neurology (CTF) 474

Lubin, H.A. (coauthor) see Nahata, Milap C., 439
Luccarotti, Richard L. (coauthor) see Matzke, Gary R., 425

Ludden, Thomas M. (coauthor) see Beach, C.L., 450, see Talbert, Robert L., 442

Ludwig, Dennis J. (author) Author's Reply: Correction in CPR Team Article (L) 849; (author) The Pharmacist as a Member of the CPR Team: Evaluation by Other Health Professionals (RPR) 463

Lupus nephritis, renal disease (CTF) 64

Lynch, R.A. (coauthor) see Ferguson, R.K., 453
Lyon, James A. (author) Cefoperazone (NDE) 7; (coauthor) see Garzone, Pamela, 507, 615

Lysine, treatment of herpes simplex virus (DIAS) 186

M

MacCra, Mary E. (author) Extravasation: A Hazard of Intravenous Therapy (A) 713

MacKichan, Janis J. (coauthor) see Reitz, Jeffrey A., 437
Magnesium sulfate, cardiovascular disease (CTF) 760; interactions, aminoglycosides (CTF) 674

Main, James Allen, VIP (WNC) 607
Majerus, Thomas C. (author) Author's Reply: Comment on Care of the Critically Ill (L) 558; (coauthor) see Elenbaas, Robert M., 722

Major, David A. (coauthor) see Massaro, Frank J., 368
Mann, Henry J. (author) Cimetidine-Associated Thrombocytopenia (CR) 126

Marijuana, pediatrics (CTF) 63
Marquardt, Eric D. (coauthor) see Anderson, Donald A., 847

Marlin, Susan S. (author) Comment on Verapamil Evaluation (L) 206

Mars, R. (coauthor) see Hughes, G., 436
Mars, Xavier (author) Drug Prescribing and Use Among Elderly People in Spain (A) 378

Massaro, Frank J. (author) Scotomas Secondary to Digoxin Intoxication (CR) 368

Mastrani, Peter (coauthor) see Weber, Stanley S., 523
Materson, Barry J. (author) Slow-Release Oxprenolol Compared with Oxprenolol in Hypertensive Patients: a Multicenter Clinical Trial (RPR) 51

Matzke, Gary R. (author) Author's Reply: Comments and Corrections on Dosing Guidelines (L) 911; (author) Gentamicin and Tobramycin Dosing Guidelines: An Evaluation (A) 425; Protein Binding of Phenytoin, p-Hydroxy Phenytoin and HPPH Glucuronide in Patients with End-Stage Renal Disease (ab) 443; (coauthor) see Halstenon, Charles E., 786

May, C.A. (author) Methyldopa Does Not Alter Digoxin Disposition (ab) 443

Mayersohn, Michael (author) Creatinine Clearance and Urine Flow (L) 131

McCart, Gary M. (coauthor) see Sobel, Kerry G., 539
McConnell, Warren E., VIP (WNC) 607

McElroy, James C. (author) Pharmacist Involvement in Patient Education in Northern Ireland (ab) 437

McGovern, Brian (coauthor) see DeMonaco, Harold J., 547

McGraw, Benjamin F. (coauthor) see Bryant, P.J., 445
McKenzie, Michael W. (coauthor) see Elliott, Gary T., 12

McLeod, Donald C. (coauthor) see Zola, Elizabeth M., 411; (editor) Drug Selection Perspectives, 411

Meathall, Robert E. (author) Comment on Chlorpropamide Overdose (L) 753

Meclofenamate, effect of probenecid on disposition (ab) 453

Medical devices, reporting problems (E) 240
Medicare, updating conditions for small hospitals (WNC) 485

Medication counseling, see Patient information
Medication refill, cost-effectiveness of a medication refill reminder system (ab) 441

Medroxyprogesterone, influence on theophylline disposition (ab) 434

Mefenamic acid, seizure following overdose (CR) 204
Mendel, Stephen A. (author) Topical Sclerotherapy of Esophageal Varices (CR) 640

Menendez, R. (coauthor) see Howick, J., 445
Menstruation, OTC products reviewed (WNC) 398

Messing, R. (coauthor) see Closson, Richard G., 449
Messori, Andrea (author) A New Programmable Calculator Procedure for Individualizing Phenytoin Dosage (A) 890; (author) Author's Reply: Comment on Kinetic Predictions of Serum Drug Concentrations (L) 654; (author) Pharmacokinetic Predictions Based on a Variable Dosage Frequency in Chronic Treatment (RPR) 290

Metaproterenol, changed to OTC (WNC) 154
Methimazole, pediatrics (CTF) 303

Methotrexate, adverse reactions, gynecomasia (CTF) 761, paronchia (CTF) 925; oncology (CTF) 475

Methoxyflurane, associated with water loss (A) 177
Methyldopa, adverse reactions, retroperitoneal fibrosis (CTF) 851; and digoxin disposition (ab) 443; associated with prolonged diarrhea (CR) 462

Methylprednisolone, pulmonary disease (CTF) 224, 851; pulse therapy in systemic lupus erythematosus (DIAS) 342; rheumatology (CTF) 141; urology (CTF) 304

Methylxanthines, asthma, treatment, combined with beta-adrenergic agonists (RPR) 490

Metoclopramide, adverse reactions, acute dystonic reaction and respiratory failure (CTF) 851; endocrinology (CTF) 140; interactions, cimetidine (A) 114; patients with renal failure (DIAS) 264; psychiatry (CTF) 304

Metolazone, hyponatremia (A) 176
Metoprolol, cardiovascular disease (CTF) 474; interactions, ranitidine (CTF) 851

Metronidazole, adverse reactions, grand mal seizures, coma, behavior abnormalities (CTF) 475; dermatology (CTF) 591; for giardiasis and amebiasis in pregnancy (DIAS) 188; gastroenterology (CTF) 63

Micafungin, immunosuppression in acquired immune deficiency syndrome (A) 801; infectious disease (CTF) 140; interactions, phenobarbital (CTF) 475; pediatrics (CTF) 761; pharmacokinetics in patients with alcoholic liver disease (ab) 436

Metzler, D. (coauthor) see Rodman, John, 448
Meyer, M.C. (coauthor) see Comstock, T.J., 453; see Straughn, Arthur B., 451

Mezlocillin, infectious disease (CTF) 383
Mianserin, psychiatry (CTF) 384

Michaelis-Menten equation, programmable solution (L) 559

Miconazole, fungal infections, associated with acquired immune deficiency syndrome (A) 803
Midazolam, anesthesia (CTF) 139

Milavetz, G. (author) The Pharmacokinetics of Tobramycin in Patients with Cystic Fibrosis (ab) 449
Miller, Cynthia R. (coauthor) see Kaul, Alan F., 835

Miller, Del D. (author) Cimetidine's Effect on Steady-State Serum Nortriptyline Concentrations (CR) 904, (author) Serum Haloperidol Concentrations and Clinical Response in Acute Psychosis (ab) 445

Miller, John B. (coauthor) see Mann, Henry J., 126
Milton, John A. (coauthor) see Lewis, Thomas W., 469

Minocycline, infectious disease (CTF) 924
Mirtalio, Jay M. (author) A Key to the Literature of Total Parenteral Nutrition (A) 189; (author) Effect of Nitrogen Intake on Urea Appearance in Patients Receiving Total Parenteral Nutrition and Hemodialysis (ab) 434; (coauthor) see Kudsk, Kenneth A., 501

Miser, A.W. (coauthor) see Nahata, Milap C., 435
Miskinski, Joseph (coauthor) see Wagner, Jon C., 544

Mithramycin, treatment of hypercalcemia (A) 17
Mitsuoka, J. Chris (author) Comment on Monitoring Aminoglycoside Serum Levels (L) 49; (author) Comment on Theophylline Dosing (L) 469; (coauthor) see Hattersley, Paul G., 632

Mojaverian, P. (coauthor) see Ricci, M.L., 443
Monooctanoin, for dissolution of residual cholesterol gallstones (WNC) 318

Moon, Steven B. (author) Comment on Orphan Drugs (L) 912

Moore, Robert (author) Reporting Problems with Medical Devices (E) 240

Moore, Steven R. (author) Cognitive Variants in the Elderly: An Integral Part of Medication Counseling (G) 840; (author) Receipt of Prescription Drug Information by the Elderly (G) 920

Mordell, J. Solon, editorial comment on (E) 45; tribute to (WNC) 319

Morell, Ferran (author) Choline Theophyllinate Every Eight Hours (L) 133; (author) Combined Methylxanthines and Beta-Adrenergic Agonists in the Treatment of Severe Asthma (RPR) 820

Morphine, anesthesia (CTF) 222, 591; inhibition of theophylline clearance (ab) 443; interaction with cimetidine (CR) 60, (A) 113; intrathecal administration (DIAS) 720; oncology (CTF) 384; pharmacokinetics in children with cancer (ab) 435

Morris, Suzanne M. (coeditor) see Hart, Linda L., 629, 718, 808

Morris, Van Cleve (coauthor) see Fisher, Diane J., 210
Moulton, Jonathan S. (coauthor) see Massaro, Frank J., 368

Moxalactam, adverse reactions, bleeding diathesis (CTF) 384, hypoprothrombinemia, hemorrhage, pseudomembranous colitis, fungal superinfection (CTF) 475; antibiotic penetration in abdominal infection (CR) 277; clinical summary (A) 619; infectious disease (CTF) 223, 924; interactions, alcohol (CTF) 141; intravenous therapy (CTF) 140;

pharmacokinetics (A) 512; steady-state pharmacokinetics (ab) 439; therapy for nosocomial gram-negative pneumonias (ab) 433

Mrazik, T.J. (author) Drug-Related Problems in Patients Presenting to an Emergency Services Area (ab) 449
Mueller, C.E. (author) Haloperidol-Overdose-Induced Torsade de Pointes (ab) 440

Murdell, D. (coauthor) see Reed, Michael D., 446
Murphy, S. (coauthor) see Howick, J., 445

Musallam, Nabil A. (coauthor) see Hattersley, Paul G., 632

Myers, C.M. (coauthor) see Slaughter, Richard L., 440
Myocardial infarction, use of intravenous streptokinase (LA) 367

N

Nahata, Milap C. (author) Decreased Absorption of Cefaclor in Short Bowel Syndrome (CR) 201; (author) Effect of Chlorophyllin on Urinary Odor in Incontinent Geriatric Patients (G) 732; (author) Pharmacokinetics of Cephalixin in Cystic Fibrosis (ab) 439; (author) Pharmacokinetics of Morphine in Children with Cancer (ab) 435; (author) The Role of the Clinical Pharmacist: Need and Priority (E) 751; (author) Tobramycin Delivery and Kinetics in Newborn Infants (ab) 439

Nafnor, Eugene (coauthor) see Warren, Duane E., 374
Nalbuphine, comparative effects and analgesic efficacy (DSP) 411

Naloxone, cardiovascular disease (CTF) 673; gastroenterology (CTF) 474; septic shock (ab) 436; toxicology (CTF) 304

Nanjil, Amin A. (author) Drug-Induced Electrolyte Disorders, 175

Naproxen, adverse reactions, eosinophilic pneumonia (CTF) 475; excretion in milk (L) 910; hypoprothrombinemia in overdose (CR) 549

Naproxen/bupropfen, adverse reactions, cognitive dysfunction (CTF) 141

National Center for Devices and Radiological Health, established in FDA (WNC) 153

Naylor, Cartha (coauthor) see Christoff, Patricia B., 516
Neidorf, Barry S. (coauthor) see Materson, Barry J., 51

Neims, A.H. (coauthor) see Hill, Malcolm R., 452
Nelson, Robert C. (coauthor) see Rector, Tom S., 377

Neomycin, adverse reactions, necrotizing enterocolitis (CTF) 384

Nephrology panel, bumetanide evaluation (NDE) 786
Nester, T.J. (coauthor) see Voelker, M.S., 447

Netilmicin, adverse effects (NDE) 87; antimicrobial spectrum (NDE) 84; availability and cost (NDE) 88; chemistry and pharmacology (NDE) 83; dosage and administration (NDE) 88; pharmacokinetics (NDE) 85; therapeutic use (NDE) 86; toxicity (NDE) 87

Neuroleptic malignant syndrome, therapy of (LA) 639
Neuroleptics, drug-induced thrombocytopenia (ab) 437

Neurology (CTF), carbamazepine, 924; chymopapain (chymodactin) 760; clonidine, 303; dextroretolene, 673; digoxin, 591; interferon, 223; lorazepam, 474; pentobarbital, 673; pergolide mesylate (ergot alkaloid) 223; phenobarbital, 384; phenytoin, 384, 474; primidone, 140; tetrahydrocannabinol, 850; valproic acid, 63, 474

Neutropenia, associated with cefotaxime (CR) 739
New Drug Evaluations, Bumetanide: A New Loop Diuretic, 786; Cefoperazone, 7; Isotretinoin in Severe, Recalcitrant Cystic Acne: A Review, 329; Ketoconazole, 169; Labetalol, 704; Netilmicin, 83; Ranitidine, 873; The Clinical Use of Intravenous Acyclovir, 623; Triazolam, 495

News and Comments see Washington News and Comments

Newton, Marian (author) Communications Skills: Catalyst for Clinical Practice in Pharmacy and Nursing (L) 467
Nicotine gum, efficacy and safety (LA) 62

Nies, A.S. (coauthor) see Bryant, P.J., 445
Nifedipine, cardiovascular disease (CTF) 140, 222, 302, 383; interactions, digoxin (CTF) 224; pulmonary disease (CTF) 761; renal disease (CTF) 851; use in premature labor (DIAS) 808; uses, two new (LA) 457

Nitrofurantoin, adverse reactions, pancreatitis (CTF) 674
Nitroglycerin, clinical pharmacology (A) 259; compatibility and stability (A) 257; dermatology (CTF) 924; gastroenterology (CTF) 383; interactions, plastics (DIR) 728; intravenous, comment on article (L) 49; personal containers (L) 754; pharmaceutical considerations (A) 255; pharmacokinetics (A) 260

Nitrous oxide, anesthesia (CTF) 383; oncology (CTF) 925

Nitzberg, David M. (coauthor) see Strathman, Irvin, 635
NONLIN, more convenient use of (L) 467

Normann, S. (coauthor) see Russell, W.L., 439
Nortriptyline, effect of smoking on plasma levels in depressed patients (ab) 449; interaction, cimetidine (CR) 904

Noud, Mary (author) Calcium Channel Blockers in Premature Labor (DIAS) 808; (author) Intrathecal Morphine (DIAS) 720

Novitch, Mark, VIP (WNC) 485

Nutrition, counseling in bulimia nervosa (LA) 815; parenteral, hypertriglyceridemia, familial type IV (CR) 459; support of the critically ill patient (CC) 501

Nutrition (CTF), heparin, 474; heparin, 760; safflower oil emulsion, 223

Nwangwu, John T. (coauthor) see Kumer, Kenneth P., 121

Nwangwu, Peter U. (coauthor) see Kumer, Kenneth P., 121

O

O'Brien, C. (coauthor) see Reed, Michael D., 446
O'Neil, Michael T. (coauthor) see Cady, William J., 645

Obesity, disposition of procainamide (A) 516; theophylline clearance in obese patients (A) 274

- Obituaries (WNC), D'Angelo, Alfred J., 689; Evans, Charles, 607; Provost, George P., 79; Shangraw, William B., 607**
- Obstetrics/Gynecology (CTF), aspirin, 140; bromocriptine, 474; clotrimazole, 924; cocaine, 761; ferrous fumarate, 674; ketoconazole, 925; oral contraceptives, 591; povidone-iodine, 850; procainamide, 223; rabies vaccine (human diploid) 63; ritodrine, 140; tamoxifen, 303; vaginal spermicides, 140, 223; zorniparic, 63**
- Occult blood tests, interactions, iron preparations (CTF) 141**
- Oddis, Joseph A., VIP (WNC) 485**
- Ogawa, Gary S., (coauthor) see Sorkin, Eugene M., 60**
- Ogawa, C. Dwayne (author) Author's Reply: Comment on Drugs, Alcohol, and Sex Review (L) 293; (author) book review, 927**
- Ohnawa, Tomoji (author) Neutropenia Associated with Cefotaxime (CR) 739**
- Okafor, Kingsley C. (coauthor) see Dozier, Nicky, 798**
- Oles, Karen S. (author) Phenytoin and Carbamazepine Serum Protein Binding in a Geriatric Patient Population (ab) 438**
- Oliff, Layne (coauthor) see Stein, Z.L.G., 376**
- Oncology (CTF), aminoglutethimide, 674; chemotherapeutic agents, 140; cisplatin, 761; dexamethasone, 850; dexamethasone sodium phosphate, 851; dimethyl sulfoxide (DMSO) 761; doxorubicin, 140; etoposide (podophyllin derivative) 591; methotrexate, 475; morphine, 384; nitrous oxide, 925; recombinant leukocyte A interferon, 223; tamoxifen, 384, 475; thiopeta, 63; transdermal scopolamine, 303**
- Ophthalmology (CTF), acetazolamide, 303; acyclovir, 223; cyclosporine, 925; delta-9-tetrahydrocannabinol, 592; indomethacin, 761; papain, 475; pilocarpine gel, 63; prednisolone, 303**
- Opinions see An Opinion, see Editorials**
- Opioids, comparative effects and analgesic efficacy (DSP) 411**
- Oral contraceptives, adverse reactions, lipid levels, effect on (CTF) 592; interactions, benzodiazepines (CTF) 592; obstetrics/gynecology (CTF) 591; rheumatology (CTF) 141**
- Oral pancreatic enzyme replacement therapy interactions, cimetidine (A) 113**
- Orphan drugs, another solution (E) 80; bill now public law (WNC) 237**
- Orphan Products Development, Office of, funds (WNC) 154**
- Oriols, Ramon (coauthor) see Morell, Ferran, 133, 820**
- Osathanondh, Rapin (coauthor) see Kaul, Alan F., 293**
- Over-the-counter medications, tamper-resistant packaging proposed (WNC) 237**
- Owen, John A., Jr. (author) Archambault: Vox Clamantis in Deserto (E) 776**
- Oxprenolol, slow-release compared with oxprenolol in hypertensive patients (RPR) 51**
- P**
- Pagliari, Louis A. (author) Comment on APhA Resolution (L) 469**
- Paone, R.P. (coauthor) see LeBel, Marc, 908**
- Papain, ophthalmology (CTF) 475**
- Paraldehyde, pediatrics (CTF) 925**
- Pargolide mesylate, ergot alkaloid, neurology (CTF) 223**
- Pericardial disease, anesthesiology (CTF) 591**
- Perphenazine, interactions, tricyclic antidepressants (CTF) 304**
- Perrin, J.H. (author) see Bendayan, R., 435**
- Perry, Paul J. (author) The Effects of Smoking on Nortriptyline Plasma Levels in Depressed Patients (ab) 449**
- Personnel Placement see ADVERTISERS**
- Peterson, Gregory M. (author) Computer-Assisted Drug Therapy for Epilepsy (RPR) 123**
- Pevonka, M. Peter (coauthor) see Lapierre, Ginette, 39**
- PharmacCE test questions, 75, 150, 235, 312, 395, 482, 603, 685, 772, 860, 938**
- Pharmaceutical education see Education, pharmaceutical**
- Pharmaceutical industry see Industry, pharmaceutical**
- Pharmaceutical manufacturers see Industry, pharmaceutical**
- Pharmacist, clinical, defined, 593**
- Pharmacokinetics, acyclovir (NDE) 624; alfentanil (ab) 437; amikacin (A) 35; aminoglycosides (A) 33; (L) 375; (RPR) 906; aminophylline (CR) 202; (RPR) 465; amiodarone (A) 101; bumetanide (NDE) 787; carbamazepine (A) 812; cefmenoxime (A) 509; cefoperazone (NDE) 8; ceforamide (A) 509; cefotiam (A) 509; cefsulodin (ab) 446; cefazidime (ab) 453; cefprozil (A) 509; cefuroxime (A) 509; cephalixin (ab) 439; cephalosporins (A) 507; (RPR) 906; dosage, phenytoin, calculator procedure (A) 890; drugs, predictions (RPR) 290, (L) 653; equations, Michaelis-Menten (L) 559; etoposide (ab) 442; fluphenazine (ab) 436; gentamicin (A) 425; (L) 911; heparin (ab) 451; indocyanine green (ab) 446, (ab) 454; isotretinoin (NDE) 303; kanamycin (A) 35; ketoconazole (NDE) 170; labetalol (NDE) 705; methods (ab) 447, (L) 653; metronidazole (ab) 436; morphine (ab) 435; moxalactam (ab) 447, (L) 512; nifedipine (NDE) 85; nitroglycerin (A) 260; phenobarbital (CR) 908; phenytoin (A) 890; piroperone (ID) 894; procainamide (ab) 447; testosterone (ab) 447; theophylline (L) 132, (CR) 202 (RPR) 465, (L) 847; ibuprofen (A) 425, (ab) 439, (ab) 446, (ab) 449, (A) 529, (L) 911; triazolam (ab) 447, (NDE) 496**
- Pharmacy, clinical, defined 593; institutional, hospital, Portugal, past, present, and future (IR) 843; legislation, see Legislation; research, clinical faculty, comments by AACCP president (WNC) 863, principal investigator, FDA policy (ACCP), 676; Veterans' Administration, see Veterans' Administration**
- Pharmacy education, comment on P.D. degree (L) 133; predicting success of pharmacy students in basic science and clinical clerkship courses (A) 297; see Education, pharmaceutical**
- Pharmacy industry see Industry, pharmaceutical**
- Pharmacy practice, clinical pharmacy and progress (O) 564; communication between pharmacist and patient (L) 468; communication skills, catalyst for clinical practice in pharmacy and nursing (L) 467; cost-effectiveness of a clinical pharmacist as a provider of mental health care (ab) 433; dispensing accuracy in a high-volume outpatient pharmacy (RPR) 742; drug prescribing and use among elderly people in Spain (A) 378; foreign pharmacists can take U.S. examination for licensure (WNC) 484; gap between basic sciences and clinical pharmacy practice (O) 210; geriatrics, pharmacist's perceptions (G) 134; lack of support for clinical pharmacy (L) 208; liability claims based on drug use (A) 667; patient counseling (Rho Chi Lecture Award) (A) 570; pharmacist as a member of the CPR team, evaluation by other health professionals (RPR) 463; pharmacist involvement in patient education in Northern Ireland (ab) 437; pharmacists as primary care providers (ab) 442; pilot study with auxiliary prescription labels (A) 216; prescribing authority for pharmacists (O) 660; prescribing drug therapy (L) 50; readability testing of auxiliary labels (RPR) 54; reimbursement for clinical pharmacy services (L) 293; relationships between patient variables and frequency of pharmacy counseling (RPR) 648; role of the clinical pharmacist, need and priority (E) 751; spanish labeling guide (A) 580; views of supportive personnel in Florida 576**
- Phencyclidine, pediatrics (CTF) 925**
- Phenobarbital, asphyxia lowers dosing requirements in newborns (ab) 434; effect of exchange transfusion on kinetics (CR) 901; formulations for asthma (L) 653; interactions, cimetidine (A) 114, metronidazole (CTF) 475; neurology (CTF) 384; toxicology (CTF) 64**
- Phenol, urology (CTF) 85**
- Phenoxymethylamine, use in septic shock (CC) 96**
- Phenybutazone, adverse reactions, pericarditis, salivary gland enlargement and atrial fibrillation (CTF) 64**
- Phenyphrine, adverse reactions, no reaction (CTF) 141; pediatrics (CTF) 475**
- Phenylpropanolamine, adverse reactions, acute renal failure and rhabdomyolysis (CTF) 64; cardiac arrhythmias after ingestion (CR) 737; comparison of effects of two dosage regimens on blood pressure and plasma levels (RPR) 746; toxicology (CTF) 674**
- Phenytoin, binding, serum, plasma, protein (ab) 438, (ab) 443; bulimia nervosa, treatment (LA) 815; disposition, (ab) 448; dosage, calculator procedure (A) 890; evaluation, oral loading doses (ab) 441; free-drug concentrations, pediatric patients (ab) 448; interactions, azapropazone (DIR) 106, cimetidine (A) 111, disopyramide (CTF) 64, ibuprofen (CTF) 304, quinidine (ab) 450, theophylline (CTF) 224; multiple-point maintenance dose prediction (ab) 445; neurology (CTF) 384, 474; psychiatry (CTF) 141; reactions, lymphadenopathy (CR) 460**
- Phlebitis, diazepam-induced (CR) 125**
- Phosphates, treatment of hypercalcemia (A) 17**
- Physical Assessment, The Heart (PA) 248**
- Physostigmine, geriatrics (CTF) 673; toxicology (CTF) 475**
- Pierpaoli, Paul G., VIP (WNC), 941**
- Pilocarpine gel, ophthalmology (CTF) 63**
- Pilot, Larry R., VIP (WNC) 689**
- Pimozide, dermatology (CTF) 850; psychiatry (CTF) 441**
- Pindolol, cardiovascular disease (CTF) 63**
- Pines, Wayne L. (author) New Drugs and FDA Publicity (A) 671**
- Pink, Laurence A. (author) Doctoring Titles (L) 562**
- Piperacillin, infectious disease (CTF) 303**
- Piroxicam, adverse reactions, no fecal blood loss (CTF) 64**
- Pirprofen (ID) 894**
- Pituitary, surgery, ADH imbalance (A) 886**
- Placethia, J. (coauthor) see Donn, K.H., 446**
- Plasma expanders, interaction with penicillins (A) 351**
- Pneumocystis carinii pneumonia, acquired immune deficiency syndrome, discussion, 798**
- Podrebarac, M. (coauthor) see Bryant, P.J., 445**
- Poison control, program to continue in abbreviated form (WNC) 77**
- Polymyxin B, hypokalemia (A) 177; hypomagnesemia (A) 181**
- Ponte, Charles D. (author) A Mild Case of Toxic Shock Syndrome (CR) 283; (author) A Suspected Case of Codeine-Induced Erythema Multiforme (CR) 128; (author) Author's Reply: Comment on a Case of Thiazide-Induced Hyponatremia (L) 205; (author) Carbamazepine-Induced Thrombocytopenia, Rash and Hepatic Dysfunction (CR) 642**
- Porter, R. Steven (coauthor) see Hughes, G., 436**
- Portugal, hospital pharmacy, past, present, and future (IR) 843**
- Positions open see ADVERTISING, Personnel Placement**
- Potassium, intravenous supplementation in pediatric cardiac surgery patients (ab) 439; chloride, adverse reactions, gastrointestinal lesions (CTF) 475; iodide, over-the-counter sales (WNC) 318**
- Povidone-iodine, obstetrics/gynecology (CTF) 850**
- Powell, D.A. (coauthor) see Nabata, Milap C., 439**
- Powell, J. Robert (author) Lack of Cimetidine-Lidocaine Interaction in Patients with Suspected Myocardial Infarction (ab) 445; (coauthor) see Donn, K.H., 446**
- Powell, Stephen H. (coauthor) see Kaul, Alan F., 835; (coauthor) see Vogenberg, F. Randy, 912**
- Poyner, Wesley J. (coauthor) see Kolb, Kenneth W., 375**
- Pratt, C.B. (coauthor) see Cron, William R., 448**
- Pratt, Clara C. (coauthor) see Simonson, William, 134**
- Prazosin, cardiovascular disease (CTF) 474, 760**
- Prechel, D. (coauthor) see Bauman, Jerry L., 435**
- Prednisolone, ophthalmology (CTF) 303; renal disease (CTF) 592; rheumatology (CTF) 304**
- Prednisone, adverse reactions, behavioral disorders (CTF) 304; hematology (CTF) 63**
- Pregnancy, amebiasis, drug regimen (DIAS) 187; Bendectin, comment on (E) 826; vaccines, rubella, risk to fetus (WNC) 862; valproic acid, risk of spinal bifida (WNC) 862**
- Preynilamine, interactions, lidocaine (DIR) 106**
- Prescribing, physician, effect of changing from a qualitative to a quantitative antimicrobial susceptibility test reporting system (RPR) 552**
- Primidone, catatonic schizophrenia induced (CR) 551; neurology (CTF) 140**
- Prince, Randall A. (author) Side-Effect Profiles of Newer-Generation Cephalosporins (E) 656; see Perry, Paul J., 449; see Taylor, Jerry W., 452**
- Probencid, effect on the disposition of mefloquine sodium (ab) 453; effect on the pharmacokinetics of aminophylline (RPR) 465**
- Procainamide, disposition in obesity (A) 516; high doses in chronic renal failure (CR) 279; interactions, cimetidine (CTF) 141; obstetrics/gynecology (CTF) 223; prediction of steady-state serum concentrations after administration of a sustained-release formulation (ab) 447; relationship between N-acetylprocainamide serum concentrations and oral procainamide in elderly male patients (ab) 450**
- Proctor, Richard (author) A Marginal Profession? (L) 50**
- Progesterone, for sleep apnea (LA) 736**
- Propanteline, interactions, cimetidine (A) 114**
- Propofol, adverse reactions, depression (CTF) 141; electrophysiologic variables correlated with blood levels in the chronically instrumented puppy (ab) 443; influence of age and experimental temperature on serum protein binding (ab) 435; interactions, ranitidine (CTF) 384**
- Propylthiouracil, hypocalcemia (A) 180**
- Prostaglandin E₂, cardiovascular disease (CTF) 850**
- Protein therapy, use for drug overdose (L) 292**
- Protriptyline, for sleep apnea (LA) 736; general medicine (CTF) 140; pulmonary disease (CTF) 475**
- Provost, George P., editorial comment on (E) 45; obituary (WNC) 79**
- Psi-ox, leukemia chemotherapy, resistance (WNC) 153**
- Psoralens, adverse reactions with UV light (CTF) 674**
- Psychiatry (CTF), alprazolam, 761; amitriptyline/tranylcypromine, 851; antidepressants, 674; clonidine, 592; dexamethasone suppression test, 475; diazepam, 925; haloperidol, 64; 5-hydroxytryptophan, 592; imipramine, 303; lecitin, 140; metoclopramide, 304; mianserin, 384; phenytoin, 141; pimoizide, 141; tranylcypromine, 851; zimelidine, 141**
- Psychiatry panel, triazolam evaluation (NDE) 495**
- Psychosocial drugs, use in children (E) 562**
- Psychosocial, R.J. (coauthor) see Burckart, Gilbert J., 446; (coauthor) see Venkataraman, R., 446**
- Pullan, Peter T. (coauthor) see Benzie, Jennifer L., 886**
- Pulmonary Disease (CTF), aspirin, 674; calcium antagonists, 384; isoproterenol, 384; lithium carbonate, 141; methylprednisolone, 224, 851; nifedipine, 761; protriptyline, 475; theophylline, 592, 674**

Puschett, J.B. (coauthor) see Kroboth, Patricia D., 447
Pyrimethamine, adverse reactions, component in
Fansidar, Stevens-Johnson syndrome (CTF) 304

Q

Quandt, Christine M. (author) Plasma Protein Binding of
Phenytoin in Critically Ill Patients (ab) 438
Quart, Barry D. (author) Prolonged Diarrhea Secondary
to Methylodopa Therapy (CR) 462
Quattrocchi, Frank P. (author) The Effect of Ibuprofen
on Serum Digoxin Concentrations (RPR) 286
Quee, C.K. (coauthor) see Park, Glen D., 435
Quinidine, electrocardiographic effects and time course of
the interaction with phenytoin (ab) 450; influence of
rifampin (ab) 436; interactions, amiodarone (DIR) 105,
anticonvulsants (CR) 819, digoxin (CTF) 64; pediatric
(CTF) 224
Quinine sulfate, rheumatology (CTF) 851

R

Rausch, Ralph H. (coauthor) see Hak, Larry J., 440
Rabies vaccine, obstetrics/gynecology (CTF) 63
Radomski, L. (coauthor) see Park, Glen D., 435
Raissys, V. (coauthor) see Bauer, L.A., 434
Ranitidine, adverse reactions, no effect on blood glucose
or insulin (CTF) 224, review (NDE) 878; availability
and cost (NDE) 881; chemistry (NDE) 873; dosage and
administration (NDE) 879; efficacy (NDE) 877;
evaluation (NDE) 873; gastroenterology (CTF) 383,
850; interactions, diazepam (CTF) 761; metoprolol
(CTF) 851, propranolol (CTF) 384, review (NDE) 879;
pharmacokinetics (NDE) 875; pharmacology, animal
(NDE) 874, human (NDE) 874; treatment, cimetidine-
resistant ulcers (DIAS) 629
Rapp, Robert P. (author) Parenteral Nutrition in a
Patient with Familial Type IV Hypertriglyceridemia: A
Dilemma (CR) 458
Rault, R. (coauthor) see Kroboth, Patricia D., 447
Ravenscroft, Peter J. (coauthor) see Cordingley, Frank
S., 467
Ravis, William R. (author) Comment on Calculator
Program For Adjusting Aminoglycoside Dosage (L)
375
Rawls, W. Nathan (author) book review, 926
Receptor research, developing concepts (A) 357
Recombinant leukocyte A interferon, oncology (CTF) 223
Record, Kenneth E. (author) book review, 145
Rector, Tom S. (author) Author's Reply: Clinical Scientist
or Pharmacy Administrator? (L) 377
Reed, Michael D. (author) The Efficacy and
Pharmacokinetics of a Cefsulodin/Tobramycin
Combination in Patients with Cystic Fibrosis (ab) 446;
(coauthor) see Slaughter, Richard L., 440
Reed, Ronald C. (author) Circadian Variation in Trough
Theophylline Concentrations (ab) 444
Reese, Davis R. (author) Comment on Brand of Aspirin
and Serum Levels (L) 849; (author) Comment on
Intravenous Nitroglycerin (L) 754
Regner, Michael J. (coauthor) see Ward, Thomas T., 552
Regulatory Affairs Professional Society, sixth annual
meeting (WNC) 319
Reiley, T. (coauthor) see Armstrong, D., 437
Reinders, Thomas P. (coauthor) see Carter, Barry L., 23
Reisman, L.E. (coauthor) see Ferguson, R.K., 453
Reithberg, D.P. (coauthor) see Swanson, D.J., 439
Reitz, Jeffrey A. (author) The Pharmacokinetics of
Alfentanil in Gynecological Surgical Patients (ab) 437
Renal Disease (CTF), indomethacin, 304; lupus nephritis,
64; nifedipine, 851; prednisolone, 592; zinc acetate, 64
Renal failure, associated with zomepirac (CR) 56; high-
dose procainamide (CR) 279
Renal function, consequences of drug choice and dosage
regimen for patients with impaired kidney function (A)
267
Reports see Clinical Pharmacy Case Reports; see
International Reports; see Research/Practice Reports
Research, children as subjects (WNC) 484; human,
informed consent requirements (A) 828; institutional
review board, policies (A) 831, role of (A) 828,
protocol guidelines (A) 833; pharmacy, clinical faculty,
comments by AACF president (WNC) 863, clinical,
principal investigators, FDA policy (ACCP) 676
Research/Practice Reports, aminoglycoside inactivation
by penicillins and cephalosporins and its impact on
Drug-Level Monitoring, 906; Ceforanide vs.
Cephalexin Concentrations in Total Joint
Arthroplasty, 645; Combined Methylxanthines and
Beta-Adrenergic Agonists in the Treatment of Severe
Asthma, 820; Comparison of Effects of Two Dosage
Regimens of Phenylpropanolamine on Blood Pressure
and Plasma Levels in Normal Subjects Under Steady-
State Conditions, 746; Computer-Assisted Drug
Therapy for Epilepsy, 123; Effect of Antacid on
Bioavailability of a Sustained-Release Theophylline
Preparation, 555; Effect of Ibuprofen on Serum
Digoxin Concentrations, 286; Effect of Procainamide
on the Pharmacokinetics of Aminophylline, 465; Effect
on Physician Prescribing Practices of Changing from a
Qualitative to a Quantitative Antimicrobial
Susceptibility Test Reporting System, 552; Lack of
Interference of Five New Beta-Lactam Antibiotics
With Serum Creatinine Determination, 908;
Observations on Written Communications Between
Physicians Regarding Patients' Drug Treatment
Compared with Patients' Recall, 288; Perspectives on
Digoxin Absorption from Small Bowel Resections,
121; Pharmacists' Dispensing Accuracy in a High-
Volume Outpatient Pharmacy Service: Focus on Risk
Management, 742; Pharmacokinetic Predictions Based
on a Variable Dosage Frequency in Chronic
Treatment, 290; Predictability of Serum Digoxin

Concentrations in Clinical Practice, 821; Readability
Testing of Auxiliary Labels, 54; Slow-Release
Oxprenolol Compared With Oxprenolol in
Hypertensive Patients: A Multicenter Clinical Trial,
51; The Pharmacist as a Member of the CPR Team:
Evaluation by Other Health Professionals, 463; The
Relationship Between Patient Variables and Frequency
of Pharmacist Counseling, 648
Residencies see Fellowships and Residencies
Resuing, Richard H. (coauthor) see Nahata, Milap C.,
435
Revital, all brand products seized (WNC) 78
Reye's syndrome, latest status (WNC) 238
Rheimer, Jo Ann (coauthor) see Newton, Marian, 467
Rheumatology (CTF), choline magnesium trisilicate
(trilisate) 224; colchicine, 304; cyclophosphamide, 141;
D-penicillamine, 761; dimethyl sulfoxide, 224; evening
primrose oil, 925; hydrochlorothiazide, 925;
methylprednisolone, 141; oral contraceptives, 141;
penicillamine, 224; prednisolone, 304; quinine sulfate,
851
Rho Chi Lecture Award, Dispensing in 1982, 570
Ribavirin, infectious disease (CTF) 673
Richards, A. (coauthor) see Ereshefsky, Larry, 436
Rifampin, infectious disease (CTF) 303; influence on
quinidine and digoxin therapy (ab) 436
Riley, C.A. (coauthor) see Crom, William R., 448
Ristion, K. (coauthor) see Smith, B.R., 433
Rimantadine, infectious disease (CTF) 63
Ringer, Joseph (author) Comment on Titles and Degrees
(L) 755
Ritodrine, obstetrics/gynecology (CTF) 140
Roberts, R.J. (coauthor) see Leff, Richard D., 448
Robinson, J. Daniel (coauthor) see Quattrocchi, Frank
P., 286
Robinson, Lawrence A. (author) Comment on
Intravenous Nitroglycerin (L) 49
Robinson, Lisa A. (coauthor) see Rumsfeld, Jean A.,
329; (coauthor) see Weiss, V.C., 437
Robinson, Sumner M., VIP (WNC) 485
Roca, Isabel (coauthor) see Morell, Ferran, 133
Rocci, M.L. (author) Morphine Inhibition
Theophylline Clearance (ab) 443; (coauthor) see
Grasela, Dennis M., 454; see May, C.A., 443
Rodgers, George C. (author) Quinidine Interaction with
Anticonvulsants (CR) 819
Rodman, John (author) Computer-Based Trend Analysis
of Parenteral Antibiotic Use Patterns (ab) 448
Rogers, J.F. (coauthor) see Doon, K.H., 446
Rosenbloom, David (author) Observations on Written
Communications Between Physicians Regarding
Patients' Drug Treatment Compared with Patients'
Recall (RPR), 288
Ross, J. (coauthor) see Ackerman, Bruce, 444
Rotblatt, Michael D. (author) Giardiasis and Amebiasis in
Pregnancy (DIAS) 187; (coauthor) see Hart, Linda L.,
186
Rotmensch, H.H. (coauthor) see Grasela, Dennis M., 454;
see May, C.A., 443; see Senholzi, Craig S., 445
Rotschaefer, J. (coauthor) see Ackerman, Bruce, 433, 444
Rubella vaccine, risk to fetus (WNC) 862
Rumsfeld, Jean A. (author) Isotretinoin in Severe,
Recalcitrant Cystic Acne: A Review (NDE) 329
Rumsfeld, L. (coauthor) see Weiss, V.C., 437
Russell, W.L. (author) Cimetidine and Antacids: A
Clinically Insignificant Interaction? (ab) 439
Rybak, Michael J. (coauthor) see Boike, Steven C., 56;
see Hunt, Stephanie A., 560

S

Saccar, C.L. (coauthor) see Rocci, M.L., 443
Saddique, A. (coauthor) see Fletcher, C.V., 447
Safflower oil emulsion, nutrition (CTF) 223
Sagaves, Rosalie (author) The Effects of Exchange
Transfusion on the Pharmacokinetics of Phenobarbital
(CR) 901
Saklad, Stephen R. (coauthor) see Ereshefsky, Larry, 436
Salaries, fellowship, 1983-84 survey (A) 835
Salbutamol, hypokalemia (A) 178; see also, albuterol
(CTF) 302
Salem, Ronald B. (author) Recommendations for
Monitoring Lithium Therapy (A) 346
Salicylates, toxicology (CTF) 224
Salt tablets, alert concerning (L) 377
Saltzman, Marcus B. (author) Comparison of Effects of
Two Dosage Regimens of Phenylpropanolamine on
Blood Pressure and Plasma Levels in Normal Subjects
Under Steady-State Conditions, 746
Sanders, S.W. (author) Dapsone in Dermatitis
Herpetiformis (ab) 434
Sawchuk, Ronald J. (coauthor) see Matzke, Gary R., 443
Sawyer, Dennis R. (coauthor) see Smolinske, Susan C.,
474, 591, 673; (editor) Current Therapeutic Findings,
383
Sawyer, John B. (coauthor) see Miller, Del D., 904
Scavone, Joe (author) Intrathecal Sodium Fluorescein
(DIAS) 186
Schaber, D.E. (author) Intravenous Postassium
Supplementation in Pediatric Cardiac Surgery Patients
(ab) 439
Schabile, D.H. (coauthor) see Capit, Gary C., 451
Schantz, Jerome J. (author) A Microcomputer Program
for Tobramycin Consult Services, Based on the Two-
Compartment Pharmacokinetic Model (A) 528;
(coauthor) see Carson, Herbert B., 277; see Swanson,
D.J., 439
Schlaeffer, F. (author) Cisplatin-Induced Bradycardia
(CR) 899
Schneider, Joseph R. (coauthor) see Mann, Henry J., 126
Schneeweiss, Fred (author) Obtaining Drug Information
from Pharmaceutical Manufacturers (A) 27; (coauthor)
see Seligman, Marissa, 629
Schubert, Elliot N. (coauthor) see Strathman, Irvin, 635

Schulman, Stephen G. (coauthor) see Quattrocchi, Frank
P., 286
Schwartz, H.J. (coauthor) see Reed, Ronald C., 444
Schwartz, J. (author) Warfarin-Erythromycin Interaction
(ab) 438
Schwarz, Peter A. (coauthor) see Vogenberg, F. Randy,
912
Schwinghammer, Terry L. (author) Phenytoin-Induced
Lymphadenopathy (CR) 460; (coauthor) see Fischer,
John M., 718
Scientists, clinical, comments by AACF "resident (WNC)
863
Sclerotherapy, topical, for esophageal varices (CR) 640
Scopolamine, transdermal, oncology (CTF) 303
Scotom, secondary to digoxin intoxication (CR) 368
Scott, Gayle Nicholas (author) Title Irrelevant to
Character (L) 654
Seaman, John J. (author) The Heart (PA) 248
Searcy, C.J. (author) The Effects of Pregnancy on the
Distribution and Elimination of Theophylline (ab) 452
Seclul, Elsa (coauthor) see Mas, Xavier, 378
Seifert, Randall D. (author) Heparin Kinetics During
Hemodialysis: Variation in Sensitivity, Distribution
Volume, and Dosage (ab) 451; (author) Use of
Anticholinergics in the Nursing Home: An Empirical
Study and Review (G) 470
Seizures, drug-induced, drug treatment (ab) 449
Self, Timothy H. (coauthor) see Henderson, Robert P.,
741
Seligman, Marissa (author) Clonidine Suppression Test
(DIAS) 719; (author) Ranitidine in Cimetidine-
Resistant Ulcers (DIAS) 629
Seligsohn, R. (coauthor) see Giacomini, Nicola, 452;
(coauthor) see Lau, Alan, 436
Senholzi, Craig S. (author) book review, 478; (author)
Effect of Amiodarone and Desethylamiodarone on
Digoxin Suppression of 86 Rb+ Red-Blood-Cell
Uptake In Vitro (ab) 445
Septic shock, antibiotic therapy (CC) 96; corticosteroids
(CC) 97; fluid therapy (CC) 95; management of (CC)
92; vasodilators (CC) 97; vasopressors and inotropic
agents (CC) 96
Sewell, David L. (coauthor) see Ward, Thomas T., 552
Sher, Alan (author) Primidone-Induced Tachycardia
Schizophrenia (CR) 551
Sherins, R.J. (coauthor) see Pascucci, V.L., 447
Short bowel syndrome, decreased absorption of cefaclor
(CR) 201
Sieradski, Edmund (coauthor) see Wichlinski, Leslaw M.,
812
Silveira, Carlos (coauthor) see Leal, Leslaw Marques, 843
Silver nitrate, prophylaxis of neonatal conjunctivitis (LA)
139
Silver, M.R. (coauthor) see Kroboth, Patricia D., 447
Simon, R.P. (coauthor) see Crothorn, Richard G., 449
Simon, Wayne A. (coauthor) see Clark, John E., 737
Simonson, William (author) Pharmacists' Perceptions of
Geriatric Pharmacy Practice (G) 134
Singh, A. (coauthor) see Schaber, D.E., 439
Sinkule, J.A. (coauthor) see Hatson, Paul R., 442
Sister Mary Berenice, editorial comment on (E) 45
Skilled nursing facility, evaluation of hypertensive therapy
(A) 39
Sklar, Stephen J. (coauthor) see Wagner, Jon C., 847
Slama, Thomas G. (coauthor) see Wagner, Jon C., 544
Slaughter, Richard L. (author) The Pharmacokinetics of
Sulfamethoxazole/Trimethoprim During Peritoneal
and Hemodialysis (ab) 440; (author) Theophylline
Clearance in Obese Patients in Relation to Smoking
and Congestive Heart Failure (A) 274
Slavin, R.G. (coauthor) see Defaunte, Jeffrey C., 433
Slencak, Carole A. (coauthor) see Nahata, Milap C., 732
Small, William, VIP (WNC) 239
Sofflower oil emulsion, nutrition (CTF) 223
Smith, B.R. (author) Cefmenoxime Penetration into Bile,
Cerebrospinal Fluid, Sputum, and Other Sites (ab) 433
Smith, Capt. Lamar, VIP (WNC) 689, 863
Smith, Gary D. (author) Efficacy and Safety of
Fluocortin Butyl in Adults with Perennial Rhinitis (ab)
442; (coauthor) see Milavetz, G., 449
Smith, I.L. (coauthor) see Swanson, D.J., 439
Smith, R.B. (coauthor) see Kroboth, Patricia D., 447
Smoking, relation to theophylline clearance in obese
patients (A) 274
Smolinske, Susan C. (editor) Current Therapeutic
Findings, 474, 591, 673, 760, 850, 924
Sobel, Kerry G. (author) Drug Use and Accidental Falls
in an Intermediate Care Facility (G) 539
Sodium bicarbonate, hypernatremia (A) 177
Sodium cellulose phosphate, drug approval (WNC) 397
Sodium citrate, hypernatremia (A) 177
Sodium hypochlorite, dermatology (CTF) 474
Sodium phosphate, hypernatremia (A) 177
Sodium valproate, endocrinology (CTF) 673
Sommer, Col. George A. VIP (WNC) 941
Sorkin, Eugene M. (author) Cimetidine Potentiation of
Narcotic Action (CR) 60
Sorkin, M. (coauthor) see Kroboth, Patricia D., 447
Sorption, drugs, plastics (DIR) 726
Souney, Paul F. (coauthor) see Kaul, Alan F., 293
Spangher, G.G. (coauthor) see Kaul, K.A., 453
Spanish Abstracts see Foreign Abstracts
Spanish Labeling Guide, 580
Spector, R. (coauthor) see Park, Glen D., 435
Spellacy, W.N. (coauthor) see Searcy, C.J., 452
Spriornolactone, gastroenterology (CTF) 673
Spunt, A. (coauthor) see Goff, D., 441
Stang, C. (coauthor) see Stewart, C.F., 448
Stang, John M. (author) book review, 229
Starch blockers, an update (WNC) 78; general medicine
(CTF) 303
Sturzl, T.E. (coauthor) see Venkataraman, R., 446
Stein, Z.L.G. (author) Assasin Bug Toxemia (L) 753;
(author) Ethylene Glycol Toxicity and Treatment (L)

376; (author) Torsade de Pointes: a Rare Tachyarrhythmia (L) 561
Stern, R.C. (coauthor) see **Reed, Michael D.**, 446
Stevens, Douglas R.S. (coauthor) see **Jamali, Fakhraddin**, 911
Stewart, C.F. (author) Free Phenytoin Concentrations in Pediatric Patients (ab) 448
Stewart, Ronald B. (author) book review, 595; (coauthor) see **Bandayan, R.**, 435; see **Darzentas, Lazarus J.**, 555; see **Lapierre, Ginette**, 39
Stille, I.L. (author) The Pharmacokinetics of Theophylline in Premature Infants During the First Day of Life (ab) 440
Stimmel, Glen L. (coauthor) see **Kook, K.A.**, 453; see **Vlases, Peter H.**, 593
Stone, F.M. (coauthor) see **Schaber, D.E.**, 439
Storb, R. (coauthor) see **Yee, Gary C.**, 451
Strand, L. (coauthor) see **Ackerman, Bruce**, 444
Strasberg, B. (coauthor) see **Bauman, J.L.**, 435; see **Hoff, J.V.**, 440
Strate, R. (coauthor) see **Ackerman, Bruce**, 444
Strathman, Irvin (author) Hypoglycemia in Patients Receiving Disopyramide Phosphate (A) 635
Strough, Arthur B. (author) In Vitro Prediction of Steady-State Fluctuations in Theophylline Concentrations (ab) 451; (coauthor) see **Comstock, T.J.**, 453
Streptokinase, adverse reactions, Guillain-Barre syndrome (CTF) 674; cardiovascular disease (CTF) 222, 303; for acute myocardial infarction (LA) 367
Strickland, B.R. (author) Management of Diabetic Children by Behavior Modification and Blood Glucose Monitoring (ab) 438
Suarez, E. (coauthor) see **Ferguson, R.K.**, 453
Sucralate, adverse reactions, duodenal ulcer (CTF) 141; interactions, warfarin (CTF) 674
Sugar, safe at current consumption levels (WNC) 239
Sulfamethoxazole/trimethoprim, pharmacokinetics during peritoneal and hemodialysis (ab) 440
Sulfasalazine, adverse reactions, agranulocytosis, erythroid hypoplasia, plasmocytosis (CTF) 224, glandular fever-like illness (CTF) 224, systemic lupus erythematosus (CTF) 141
Sulfipyrazole, interactions, warfarin (CTF) 64
Sulfisoxazole, pediatric use (CTF) 674
Sulfiting agents, FDA lists agents generally recognized as safe (WNC) 397; further update (WNC) 485
Sulindac, adverse reactions, neutropenia complicated by pseudomonal septicemia (CTF) 224, renal toxicity (CTF) 304, adverse reactions, splenomegaly, lymphadenopathy (CTF) 141; interactions, dimethyl sulfoxide (CTF) 851
Surveys see Data collection
Swanson, B.N. (coauthor) see **May, C.A.**, 443; see **Senholzi, C.S.**, 445
Swanson, D.J. (author) Steady-State Moxalactam Pharmacokinetics: Noncompartmental vs. Two-Compartmental Analysis (ab) 439
Swiryn, S. (coauthor) see **Bauman, Jerry L.**, 435
Syndrome Malin, Therapy of (LA) 639
Systemic lupus erythematosus, steroid pulse therapy (DIAS) 342

T

Tachyarrhythmias, treatment with amiodarone (A) 100
Tackitt, Cmdr. R.D., VIP (WNC) 863
Taketomo, Robert T. (author) Comment on Programmable Calculators (L) 48; (author) Predictability of Serum Digoxin Concentrations in Clinical Practice (RPR) 821
Talbert, Robert L. (author) Vancomycin Clearance During Chronic Ambulatory Peritoneal Dialysis (ab) 442
Tamoxifen, hypercalcemia (A) 180; obstetrics/gynecology (CTF) 303; oncology (CTF) 384, 475
Tannenbaum, Rene (coauthor) see **May, C.A.**, 443
Tardive dyskinesia, use of diazepam (A) 323
Taylor, A. Thomas (coauthor) see **Graves, Terri**, 130
Taylor, Jerry W. (author) Multiple-Point Maintenance Dose Prediction of Phenytoin (ab) 452
Taylor, William J. (coauthor) see **Davidson, Karen H.**, 229
Technetium-99m, pediatrics (CTF) 761
Tendi, Enrico (coauthor) see **Messori, Andrea**, 290, 890
Teratogenicity, Bendectin, comment on (E) 826; vaccines, rubella (WNC) 862; valproic acid, spina bifida (WNC) 862
Test questions see PharmACE test questions, 75, 150, 235, 312, 395, 482, 603, 685, 772, 860, 938
Testolactone, steady-state pharmacokinetics (ab) 447
Tetanus toxoid, adverse reactions, anaphylactic reaction (CTF) 64; general medicine (CTF) 760
Tetracycline, for traveler's diarrhea (DIAS) 265; prophylaxis of neonatal conjunctivitis (LA) 139
Tetrahydrocannabinol, neurology (CTF) 850
Theophylline, absorption characteristics of a sustained-release sprinkle for infants and young children (ab) 445; antacid effect on bioavailability of a sustained-release preparation (RPR) 555; body weight effect on volume of distribution in acute exacerbations of reversible airway disease (ab) 442; charcoal influence on dosing regimen on elimination (ab) 435; circadian variation in trough concentrations (ab) 444; clearance in obese patients in relation to smoking and congestive heart failure (A) 274; clearance inhibited by morphine (ab) 443; decrease in clearance after administration of erythromycin (CR) 370; diurnal variation in elimination (ab) 452; dosage, determination (CR) 202, (L) 847; in vitro prediction of steady-state fluctuations (ab) 451; interactions, carbamazepine (CTF) 475, cimetidine (A) 111, phenytoin (CTF) 224; medoxyprogesterone influence on disposition (ab) 434; pediatrics (CTF) 63, 64, 674; pharmacokinetics, dosage (CR) 202, (L) 847, premature infants (ab) 440,

probenecid effect (RPR) 465; predictability of concentrations in patients with acute exacerbations of obstructive airway disease (ab) 443; pregnancy effect on distribution and elimination (ab) 452; pulmonary disease (CTF) 592, 674; sustained-release (L) 133; toxicity, a consequence of congestive heart failure (CR) 59; toxicology (CTF) 592, 851
Therapeutic findings see Current Therapeutic Findings, 62, 139, 222, 302, 383, 474, 591, 673, 760, 850, 924
Therapeutic Frontiers Lecture see American College of Clinical Pharmacy, 357
Thiopental, effect on serum pentobarbital concentrations (ab) 441
Thiotepa, oncology (CTF) 63
Thomas, E.D. (coauthor) see **Yee, Gary C.**, 451
Thomas, John (author) Comment on DEHP Toxicity (L) 292
Thomas, Richard (author) Comment on Care of the Critically Ill (L) 558
Thrombocytopenia, cimetidine-associated (CR) 126
Tindula, Robert J. (author) Aminoglycoside Inactivation by Penicillins and Cephalosporins and its Impact on Drug-Level Monitoring (RPR) 906
Tinidazole, infectious disease (CTF) 63
Tininitali, Judith E. (coauthor) see **Boike, Steven C.**, 56
Toback, J. (coauthor) see **Gale, Peter**, 434
Tobramycin, delivery and kinetics in newborn infants (ab) 439; efficacy and pharmacokinetics of combination with cefsulodin in cystic fibrosis patients (ab) 446; evaluation of dosing guidelines (A) 425; microcomputer program for consult services (A) 528; pharmacokinetics, in patients with cystic fibrosis (ab) 449, on a microcomputer (A) 35
Tocainide, cardiovascular disease (CTF) 924
Tofte, R. (coauthor) see **Ackerman, Bruce**, 433, 444
Tolbutamide, hyponatremia (A) 175
Tolmetin, adverse reactions, zomepirac, anaphylactoid reactions (CTF) 761
Toluene, toxicology (CTF) 64
Torsade de pointes, a rare tachyarrhythmia (L) 561
Total parenteral nutrition, a key to the literature (A) 189; effect of nitrogen intake on urea appearance (ab) 434
Tori, F. (coauthor) see **Schlaeffer, F.**, 899
Toxic shock syndrome, mild case (CR) 283
Toxicology (CTF), amoxapine, 304; aspirin, 304; caffeine, 64; cimetidine, 141; dapsone, 925; digoxin-specific fab antibody fragments, 224; formaldehyde, 475; lead, 925; naloxone, 304; pentachlorophenol, 475; phenobarbital, 64; phenylpropanolamine, 674; pyrimethamine, 475; salicylates, 224; theophylline, 592, 851; toluene, 64
Tractow, D. (coauthor) see **Armstrong, D.**, 437
Translations see Foreign Abstracts, 71, 146, 231, 307, 390, 479, 597, 680, 769, 856, 934
Tranylpromine, psychiatry (CTF) 851
Traugh, Cathy (coauthor) see **Ponte, Charles D.**, 283
Traveler's diarrhea, prevention and treatment (DIAS) 265
Trazodone, adverse reactions, ventricular arrhythmias (CTF) 851
Triamcinolone acetonide, dermatology (CTF) 850
Triazolam, availability and cost (NDE) 499; clinical studies (NDE) 496; dosage and administration (NDE) 499; drug interactions (NDE) 499; pharmacokinetics (NDE) 496; pharmacokinetics and psychomotor effects in dialysis patients, effect of aluminum hydroxide on absorption (ab) 447; pharmacology (NDE) 495; side effects and adverse reactions (NDE) 498; toxicity (NDE) 498
Tricyclic antidepressants, interactions, perphenazine (CTF) 304
Trimethoprim, dermatology (CTF) 223; infectious disease (CTF) 140, 383
Trimethoprim/sulfamethoxazole, for traveler's diarrhea (DIAS) 266; immunosuppression in acquired immune deficiency syndrome (A) 801; infectious disease (CTF) 140
Troche, Sandra M. Fabrega (author) Correction to Self-Medication Abuse or Misuse (L) 469
Trombly, Jr., John H. (author) Comment on a Case of Thiazide-Induced Hyponatremia (L) 205
Troyer, W. (coauthor) see **Zell, Michele**, 442
Tryptophan, general medicine (CTF) 924
Tse, C.S. Ted (coauthor) see **Burnfield, Jean A.**, 329
Tsuang, M.T. (coauthor) see **Perry, Paul J.**, 449
Tylenol, extra-strength, return to the marketplace (WNC) 239

U

Uden, Donald L. (coauthor) see **Schaber, D.E.**, 439
Ueberroth, A. James, VIP (WNC) 485
Ulcers, cimetidine, adverse reactions, thrombocytopenia (CR) 126, gastroenterology, treatment (CTF) 760, interactions, methadone (CR) 60; ranitidine, cimetidine-resistant (DIAS) 629, gastroenterology, treatment (CTF) 850; sucralate, adverse reactions, perforation (CTF) 141
Unit-of-use packaging, legal standard (E) 400
United States Adopted Names, editorial, 608
United States Pharmacopoeial Convention, beyond-use dating statement proposed for USP-NF, No-ctr 1; George P. Provost dies, Fb-ctr 3; Heller attends SKF dialogue, Ap-ctr 2; Heller elected treasurer of National Council on Patient Information and Education, Fb-ctr 1; hormone workshop proceedings, available, Fb-ctr 4; hosts Colorado pharmacy extern, No-ctr 3; joint pharmacy—osteopathic medicine leaflet program established, Se-ctr 1; Lewis J. Leeson elected to committee of revision, Fb-ctr 4; meet the committee of revision, No-ctr 4; NARD launches leaflet program using USP DI data base, No-ctr 1; NCPIE task force campaign to improve patient communications, Se-ctr 3; new monograph for krypton, Ap-ctr 4; news and notes, No-ctr 3; open conference a success, Se-ctr 4;

open conference on standards for parenteral products, Fb-ctr 2; Reagan assistant commends USP DI, Ap-ctr 1; staff makes presentation at NABP meeting, Se-ctr 1; Supreme Court notes USP in generic case, Se-ctr 3; updated edition of About Your Medicines now available, Fb-ctr 2; urology advisory panel formed, Se-ctr 4; USAN 1994 published, Se-ctr 4; USP develops antimicrobial tips, Fb-ctr 1; USP DI leaflet program expands, Ap-ctr 3; USP meets with MPhA special committee on required publications, Ap-ctr 1; USP staff on the road, Ap-ctr 2; USP staff receive research awards, Fb-ctr 1; USP-NF fourth supplement addendum published, No-ctr 2; 1993-94 fellowships awarded, Se-ctr 2
United States Public Health Service see USPHS News
Urinary incontinence, geriatrics (CTF) 303
Urinary odor, effect of chlorophyllin in incontinent geriatric patients (G) 732
Urology (CTF), cinoxacin, 64; cisplatin, 141; gentamicin, 674; methylprednisolone, 304; phenol, 851
Ursodeoxycholic acid, gallstone dissolution (LA) 302; gastroenterology (CTF) 63
USP Dictionary of Drug Names, editorial, 608
USPC see United States Pharmacopoeial Convention
USPHS News (WNC), computer feedback as a tool for modifying physician prescribing behavior, 687; condyloma acuminatum—1966-1981, 687; elevated risk of pelvic inflammatory disease among women using the Dalkon Shield, 606; herpes treatment—an update, 774; human T-cell leukemia virus infection with AIDS, 606; influenza surveillance summary, 1982-1983 season, 775; policies for handling misconduct in science, 687; prevention of acquired immune deficiency syndrome, 398; pseudomonas pickettii colonization, 940; rubella vaccine during pregnancy, 862; safe handling of parenteral antineoplastic drugs, 238; safety of hepatitis B virus vaccine, 399; surveillance of acute respiratory infections, 687; tribute to J. Solon Mordell, 319; update: acquired immunodeficiency syndrome (AIDS) 775; valproate: a new cause of birth defects, 862; valproic acid and spina bifida, 152

V

Vaccines, influenza, composition recommended (WNC) 689; rubella, risk to fetus (WNC) 862
Vaginal spermicides, obstet./gynecology (CTF) 140, 223
Valenza, Tommaso (coauthor) see **Messori, Andrea**, 890
Valproic acid, diurnal variability in clearance (ab) 434; interactions, anticonvulsants (CTF) 384; link to spina bifida (WNC) 152; neurology (CTF) 63, 474; spina bifida, birth defect risk (WNC) 862
van Dalen, Roelof (coauthor) see **Vree, Tom B.**, 267
van der Klein, Eppo (coauthor) see **Vree, Tom B.**, 131
Vancomycin, clearance in chronic ambulatory peritoneal dialysis (ab) 442; comparison of radioimmunoassay and fluorescent polarization immunoassay for measurement of serum concentrations (ab) 444; infectious disease (CTF) 63, 223
Varano, Carmine (author) Alert Concerning Salt Tablets (L) 377; VIP (WNC) 607
Varicella-zoster vaccine, pediatrics (CTF) 475
Vasopressin, gastroenterology (CTF) 223
Veneri, Robert (coauthor) see **Boike, Steven C.**, 56
Venkataramanan, R. (author) Cyclosporine A Removal by Hemodialysis (ab) 446; (coauthor) see **Burckart, Gilbert J.**, 446
Verapamil, adverse reactions, atrioventricular junctional rhythm (CTF) 384; cardiovascular disease (CTF) 140, 223, 591, 850; use in premature labor (DIAS) 808
Veterans' Administration, legislation, central office appointments (E) 864
Vidarabine, infectious disease (CTF) 140
Villar, L. Alberto (coauthor) see **Prince, Randall A.**, 656
Vincristine, hematology (CTF) 591
VIP News (WNC), Adams, John G., 863; Asbaugh, Richard, 319; Carlin, Herbert S., 607; DeNicola, Romulus L., 941; Doluisio, James, 607; Fay, John T., Jr., 485; Goldstein, Murray, 607; Greco, Richard E., 941; Halperin, Jerome, 689; Hanson, Capt. Kenneth E., 607; Higuchi, Takeru, 607; Johnson, Kenneth B., 689; Lemberger, Louis, 607; Main, James Allen, 607; McConnell, Warren E., 607; Miller, Kenneth W., 239; Novitch, Mark, 485; Oddis, Joseph A., 485; Patterson, Arthur W., Jr., 607; Pierpaoli, Paul G., 941; Pilot, Larry R., 689; Robinson, Sumner M., 485; Small, William, 239; Smith, Capt. Lamar, 689, 863; Sommers, Col. George A., 941; Tackitt, Cmdr. R.D., 863; Ueberroth, A. James, 485; Varano, Carmine, 607; Wade, Dorothy A., 239; Wagner, John G., 399; Walton, Charles A., 863; Wurster, Dal. E., 689
Visconti, James A. (coauthor) see **Armstrong, D.**, 437; see **Nahata, Milup C.**, 439
Vitamin A, adverse reactions, hypercalcemia (CTF) 224; interactions, plastics (DIR) 729
Vitamin E, dermatology (CTF) 760
Vlases, Peter H. (author) American College of Clinical Pharmacy: Quo Vadis? (ACCP) 593; letter to FDA (ACCP) 675; president's address (ACCP) 675; (coauthor) see **Grasela, Dennis M.**, 454; see **May, C.A.**, 443; see **Senholzi, Craig S.**, 445, 478
Voda, C. (coauthor) see **Hedrick, P.J.**, 443
Voelker, M.S. (author) Prediction of Steady-State Serum Procainamide Concentrations After Administration of a Sustained-Release Formulation: Comparison of Four Methods (ab) 447
Vogenberg, F. Randy (author) Expansion of an Investigational Drug Service (L) 912
Vree, Tom B. (author) Author's Reply: Creatinine Clearance and Urine Flow (L) 131; (author) Some Consequences of Drug Choice and Dosage Regimen for Patients with Impaired Kidney Function (A) 267

W

- Wade, Dorothy A., VIP (WNC) 239
 Wagner, John G., VIP (WNC) 399
 Wagner, Jon C. (author) Comment and Case Report on Dose-Dependent Theophylline Elimination (L) 847; (author) Falsely Elevated Aminoglycoside Serum Levels in Jaundiced Patients (CR) 544
 Walczak, Paul (coauthor) see Carson, Herbert B., 277
 Waller, Elaine S. (author) The Effect of Probenecid on the Disposition of Mefenamic Acid Sodium (ab) 453
 Walton, Charles A., VIP (WNC) 863
 Ward, J.R. (coauthor) see Dahl, Stephen L., 449
 Ward, Thomas T. (author) Effect on Physician Prescribing Practices of Changing from a Qualitative to a Quantitative Antimicrobial Susceptibility Test Reporting System (RPR), 552
 Warfarin, familial resistance (CR) 281; hematology (CTF) 383; interactions, amiodarone (A) 103, broccoli (CTF) 761, erythromycin (ab) 438, succralfate (CTF) 674; sulfipyrazone (CTF) 64; prediction of dosage from initial parent response (A) 23; strategies and outcomes of a utilization study (ab) 453
 Warren, W.A. (coauthor) see Powell, J. Robert, 445
 Warren, Duane E. (author) Acute Overdose of Bromocriptine (CR) 374
 Washington News and Comments, 77, 152, 237, 317, 397, 484, 606, 687, 774, 862, 940, see also Association News, Education and Research News, FDA News, General News, HHS News, Industry News, Obituaries, USPHS News, VIP News
 Watson, W.A. (author) Dose-Dependent Duration of Lidocaine-Induced Seizures (ab) 441; (author) Serum Pentobarbital Concentrations with Thiopental Administration (ab) 441
 Waugh, Phyllis K. (author) Hypoprothrombinemia in Naproxen Overdose (CR) 549
 Weber, Robert J. (author) book review, 388
 Weber, Stanley S. (author) book review, 853; (author) Diazepam in Tardive Dyskinesia (A) 523; (coauthor) see Dionne, Roger E., 894
 Weinberger, Miles (coauthor) see Milavetz, G., 449; (coauthor) see Smith, Gary D., 442
 Weiss, V.C. (author) Oral Isotretinoin in Disorders of Keratinization (ab) 437
 Wels, P.B. (coauthor) see Swanson, D.J., 439
 Weresow, Alex (author) Corrections to Drug Information Article (L) 655
 West, Dennis P. (coauthor) see Rumsfield, Jean A., 329; see Weiss, V.C., 437
 Whitney, Jr., Harvey A.K. (author) Let Us Now Praise Famous Men (E) 45
 Wichlinski, Leslaw M. (author) Correlation Between the Total Cholesterol Serum Concentration Data and Carbamazepine Steady-State Blood Levels in Humans (A), 812
 Wiederholt, Joseph B. (author) The Effectiveness of Auxiliary Prescription Labels: A Pilot Study (A) 216
 Wightkin, William T. (coauthor) see Frank, John J., 204
 Wilensky, A. (coauthor) see Bauer, L.A., 434
 Wilkins, J. (coauthor) see Kook, K.A., 453
 Williams, H.J. (coauthor) see Dahl, Stephen L., 449
 Wilson, H. (coauthor) see Mirazik, T.J., 449
 Wilson, Judy (author) Readability Testing of Auxiliary Labels (RPR) 54
 Wood, Charles A., Jr. (author) book review, 765
 Wright, Brenda T. (coauthor) see Robinson, Lawrence A., 49
 Wulfr, Bradley G. (coauthor) see Cady, William J., 645
 Wurster, Dale E., VIP (WNC) 689

Y

- Yacobi, Avraham (author) Pharmaceutical Considerations of Nitroglycerin (A) 255; (coauthor) see Hulse, James B., 334
 Yang, S. (coauthor) see Venkataraman, R., 446
 Yavaprabas, Supachai (coauthor) see Moore, Steven R., 920
 Yeager, R.L. (coauthor) see Pascucci, V.L., 447
 Yee, Gary C. (author) Serum Cyclosporine Concentrations

After Oral Administration in Bone Marrow Transplant Patients (ab) 451

- Yost, Richard L. (coauthor) see Darzentas, Lazarus J., 555; see Lapierre, Ginette, 39
 Yu, Victor L. (coauthor) see Garzone, Pamela, 507, 615

Z

- Zaccara, Gaetano (coauthor) see Messori, Andrea, 890
 Zappoli, Roberto (coauthor) see Messori, Andrea, 890
 Zelsler, John A. (author) Comment on Antimicrobial Susceptibility Testing (L) 207; (coauthor) see Elenbaas, Robert M., 722
 Zell, Michele (author) Effect of Body Weight on the Volume of Distribution of Theophylline in Acute Exacerbations of Reversible Airway Disease (ab), 442; (coauthor) see Curtis, Robert A., 443
 Zimeldine, psychiatry (CTF) 141
 Zinc acetate, renal disease (CTF) 64
 Zola, Elizabeth M. (author) Comparative Effects and Analgesic Efficacy of the Agonist-Antagonist Opioids (DSP) 411
 Zollaghar, S. (coauthor) see Stile, L.L., 440
 Zomepirac, adverse reactions, serum sickness (CTF) 761; obstetrics/gynecology (CTF) 63; related to acute renal failure (CR) 56
 Zune, J.J. (coauthor) see Sanders, S.W., 434

ADVERTISERS

- ADIS Press International, Inc., INPHARM and REACTIONS, 799
 AIDS Pharmacy Software, IV Label Processor, 323
 Applied Therapeutics, Inc., Books Available, 326
 Burroughs Wellcome Co., Imuran, 5-6, 163-164, 327-328, 491-492; Septira IV, 156-158, ifc-Ap-242, 406-408, 691, 703; Wellcovorin, 612-613, 734-735, 780-781, 866-867
 Drug Intelligence and Clinical Pharmacy, AID-Antibiotics Indications Device, 76, 236; L'Informatore Farmaceutico, 263; Repertorio Terapeutico, 166; Stethoscopic Heart Records, 32, 109, 285, 382, 717, 807
 Drug Intelligence Publications, Handbook of Clinical Drug Data, 273
 Eli Lilly and Company, Faspak, 694-695, ifc-Dec-865-866; Keflin, 696; Kefzol, 165-166, 487-488; Mandol, 233-234, 393-394, 493-494; Nebcin, 159-160, 315-316, 409-410, 959-960; Videotape Workshop, 611, 699, 872
 Harvey Whitney Books, Psychotropic Drug Handbook, 120, 185, 301, 350, 466, 538, 684, 750, 797, 885; The Practice of Pharmacy, ibc-Ja, Feb, Mr, Ap, Ma, Je, 696, 721, 780, 893
 Lederle Laboratories, Symposium 1 and 2, 784-785
 Marion Laboratories, Inc., Cardizem, 3-4, 167-168
 Personnel Placement, 66, 143, 227, 305, 345, 386, 424, 476, 477, 481, 605, 628, 677, 686, 767, 855, 859, 931; Arizona, Tucson, University of Arizona, 67, 386, Veterans Administration Medical Center, 67; California, Fresno, VA Medical Center, 605; Canada, Edmonton, Royal Alexandra Hospitals, 677; University of Alberta, 481, 605; Colorado, Denver, General Hospital, 386; District of Columbia, Washington, Howard University, 678; Florida, Gainesville, University of Florida, 227; Jacksonville, University Hospital, 227; Miami, Jackson Memorial Medical Center, 305; Georgia, Athens, University of Georgia, 932; Atlanta, Emory University Hospital, 67, 677, 767, 859, 932; Illinois, Mattoon, Sarah Bush Lincoln Health Center, 67, 143; Peoria, Methodist Medical Center, 227; Indiana, Indianapolis, Butler

- University, 345, Methodist Hospital, 476; Israel, Jerusalem, Hadassah University Hospital, 932; Japan, Tokyo, International Education Services, 481; Kentucky, Louisville, NKC Hospitals, 481; Louisiana, Baton Rouge, School of Veterinary Medicine, 678; Maryland, Baltimore, Union Memorial Hospital, 476, University Medical System/Hospital, 678; Bethesda, National Institutes of Health, 477; Massachusetts, Boston, New England Medical Center, 678, Northeastern University, 424, Poison Control System, 677; Worcester, University Medical Center, 66; Michigan, Detroit, Children's Hospital, 66, Wayne State University, 143; Midland, Hospital Center, 424; Minnesota, Rochester, Methodist Hospital, 933; Missouri, Kansas City, University-Kansas City, 931; St. Louis, College of Pharmacy, 305; New Jersey, Piscataway, Rutgers, 929; New York, Buffalo, State University, 931, General Hospital, 931, Millard Fillmore Hospital, 933, Jamaica, St. John's University, 67; New York City, Advanced Therapeutics Communications, Inc., 477, Rochester, University Medical Center, 386; New Zealand, Auckland, ADIS Press, 143; North Carolina, Greensboro, Moses H. Cone Memorial Hospital, 227; Ohio, Columbus, Grant Hospital, 305, Ohio State University, 143, Ohio State University Hospitals, 476, 628; Texas, Austin, Brackenridge Hospital, 933, San Antonio, University Health Science Center, 931, Temple, Scott and White, 931; Virginia, Harrisonburg, Shenandoah Shared Hospital Services, Inc., 386, Richmond, Medical College of Virginia Hospitals, 227, 859; West Virginia, Morgantown, West Virginia University, 932; Wyoming, Evanston, State Hospital, 855, 932

- RANCO Programs Inc., Kinetics Software, 230
 Roche Laboratories, History and Programs, 692-693, 700-701, 782-783, 870-871; Research Grant Program, 246-247, 324-325, 404-405

INDEX ABBREVIATIONS

- A: Article
 ab: abstracts, ACCP Annual Meeting
 ACCP: American College of Clinical Pharmacy
 CC: Critical Care Therapeutics
 CR: Critical Pharmacy Case Reports
 CTF: Current Therapeutic Findings
 ctr: center insert
 DIAS: Drug Information Analysis Service
 DIR: Drug Interactions and Reactions Update
 DSP: Drug Selection Perspectives
 E: Editorial
 F: Forensic Pharmacy
 G: Geriatrics and Gerontology
 ibc: inside back cover
 ID: Investigational Drug Information
 ifc: inside front cover
 IR: International Reports
 L: Letters
 LA: Literature Analysis
 NDE: New Drug Evaluations
 O: An Opinion
 obc: outside back cover
 PA: Physical Assessment
 RPR: Research/Practice Reports
 WNC: Washington News and Comments

Statement of ownership, management, and monthly circulation of *Drug Intelligence and Clinical Pharmacy*, publication no. 126578. Owner: Drug Intelligence and Clinical Pharmacy, Inc. (a nonprofit corporation). Publisher, editor, and managing editor: Harvey A.K. Whitney, Jr. Headquarters of publisher and publication: 4906 Cooper Road, P.O. Box 42435, Cincinnati, OH 45242. Known bondholders, mortgagees, and other security holders: none. Average no. of copies each issue from November 82 to October 83 and no. copies of October 83: A. total no. copies printed (net press run) 9862, 10400; B. paid circulation (1) single copy sales 0, 0; (2) mail subscription 8008, 9763; C. total paid circulation 8008, 9763; D. free distribution 1569, 412; E. total distribution (C + D) 9577, 10175; F. office use, left over, etc. 285, 225; G. total (E + F) 9862, 10400. No. of issues published annually: 11. Date of filing: 30 September 1983.

